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Abstract
Cardiogenic shock and cardiac arrest still have a poor prognosis with a high mortality rate.
Extracorporeal membrane oxygenation is increasingly used for the treatment of cardiogenic
shock; it is an indispensable therapy for the acute treatment of patients with cardiogenic
shock and cardiac arrest. However, extracorporeal membrane oxygenation has a significant
risk of complications. An important pitfall of extracorporeal membrane oxygenation, which
can highly impair patient outcome, is inappropriate left ventricular unloading. A number of
approaches have been suggested for dealing with left ventricular unloading during extracor-
poreal membrane oxygenation. Nevertheless, each of the currently existing methods requires
further intervention; the nowadays methods can be the reason of additional complications
such as bleeding, infection, and prolong recovery time of extracorporeal membrane oxygena-
tion treated patients. The left ventricular decompression, during extracorporeal membrane
oxygenation therapy, is associated with significant improvement of the left ventricular func-
tion. Therefore, the development of a mini-invasive method of left heart decompression is
a significant issue in extracorporeal membrane oxygenation therapy. The purpose of this
doctoral thesis is to develop an alternative method of left ventricular unloading or left ven-
tricular overload reduction, which has the potential for reducing the invasiveness of left
ventricular unloading during veno-arterial extracorporeal membrane oxygenation therapy,
based on modeling, simulation, and experiments. Data of hemodynamic and cardiac perfor-
mance parameters were obtained from porcine models of cardiogenic shock; some of these
data were used for numerical modeling and numerical simulations in the Modelica modeling
language (Modelica Association) in the Dymola (Dassault Systemes) modeling environment
and using the components from Physiolibrary 2.3.1. The statistical analysis of obtained data
from a porcine model of cardiogenic shock was conducted by using GraphPad Prism 5.0
software (GraphPad, USA) and R 3.5.3 software (The R Foundation, Vienna, Austria). The
drafts of the double lumen arterial cannula for extracorporeal membrane oxygenation was
created in AutoCAD software. An experimental study in a porcine model of cardiogenic
shock confirmed the undesirable negative effects of veno-arterial extracorporeal membrane
oxygenation on left ventricular performance parameters in a flow-dependent manner. The
simulation study indicated that the double lumen arterial cannula cannula for veno-arterial
extracorporeal membrane oxygenation with 10 Fr drainage lumen achieves reduction of left
ventricular loading, and it takes into account human physiological features. With decreasing
venous cannula size, the percentage of left ventricular loading during veno-arterial extracorpo-
real membrane oxygenation is decreased without an increase of double lumen arterial cannula
size. An experimental study in a porcine model of cardiogenic shock confirms that with the
application of double lumen arterial cannula instead of the standard arterial cannula dur-
ing veno-arterial extracorporeal membrane oxygenation, there is a significant improvement
in selected hemodynamic parameters. Among other things, biomedical engineering involves
advising manufacturers of medical devices on promising improvements based on clinical expe-
rience, the application, and implementation of medical technologies to optimize the delivery
of medical care. These aspects of biomedical engineering are realized in this doctoral thesis.
The double lumen arterial cannula presents a promising solution and has the potential for
reducing the invasiveness of left ventricular unloading during veno-arterial extracorporeal
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membrane oxygenation therapy. It is intended that the double lumen arterial cannula will
help to mitigate such extracorporeal membrane oxygenation complications as left ventricular
overload; furthermore, eliminating the complications of current methods for left ventricular
decompression, such as an additional source of bleeding, infection, and longer recovery time
of extracorporeal membrane oxygenation treated patients.
Key words: cardiogenic shock, cardiac arrest, extracorporeal membrane oxygenation ther-
apy, left ventricular overload, unloading, peripheral cannula, experimental study, modeling,
simulation
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1 Introduction
Cardiogenic shock (CS) and cardiac arrest (CA) still have an unfavorable prognosis with a
high mortality rate despite numerous efforts in diagnosis and therapy [78]. Patient prognosis
significantly depends on the time between CS or CA and the restoration of adequate end-
organ perfusion [41]. Extracorporeal Life Support (ECLS) is an indispensable therapy for
the acute treatment of patients with CS and CA [41, 120, 78]. The important advantages of
ECLS are its relative ease of implantation and an immediate reversal of inadequate systemic
perfusion [24].
Extracorporeal life support or membrane oxygenation support (ECMO) is a mechanical
device that supports or replaces heart and/or lung functions. ECMO is accepted worldwide
as a lifesaving treatment; this technology has been used for more than thirty years [85].
ECMO has been a standard treatment for respiratory failure in newborn infants and children
for many years [85, 95]; nonetheless, this technology has been applied to adult respiratory
and cardiac failure throughout the world.
ECMO can be used for days or weeks to support or replace lung and/or heart function,
leading to recovery of failing organs; nevertheless, the impact of ECMO on left ventricular
(LV) unloading is still debated. ECMO provides excellent support for circulation; however,
the capacity of ECMO to effectively assist the heart, notably the LV, is limited [68].
Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has been shown to pro-
vide some degree of LV unloading during short duration of ECMO therapy [18], but it is very
important to provide an effective left heart decompression while increasing the duration of
ECMO support [68, 122].
Poor LV decompression, during VA-ECMO therapy, frequently can lead to pulmonary
edema, pulmonary hemorrhage; it may results in dilatation of the left heart, deterioration
of heart performance, and reduced subendothelial perfusion leading to myocardial ischemia
[120, 44, 38].
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A number of approaches have been suggested for dealing with LV unloading. Each of
the current methods for LV decompression during VA-ECMO, requires further intervention
which increases the invasiveness of the method and thus does not respond to current trends
in mini-invasive performance. Therefore, the development of a less-invasive method than the
current existing methods, for left heart decompression is a significant area of investigation in
ECMO therapy. In this doctoral thesis, the development of such an alternative method of
LV unloading, which has the potential for reducing the invasiveness of LV unloading during
VA-ECMO therapy is described. This doctoral thesis deals with using of a double lumen
arterial cannula (DLAC) for VA-ECMO, as an alternative method for the reduction of left
heart loading in ECMO treated patients, and the impact of DLAC on LV decompression
during ECMO.
The doctoral thesis is composed of six chapters, each of them dealing with different
aspects of ECMO in the therapy of CA and CS. Following an introductory chapter, Chapter 2
focuses on the current state of the VA-ECMO in the therapy of CA and CS. The chapter
highlights ECMO therapy and hemodynamic and cardiac performance parameters in ECMO
treated individuals with CA and CS. The chapter describes the pitfall of the VA-ECMO
therapy as LV overload, provides an overview of the methods of LV unloading during ECMO
therapy and deals with the peripheral cannulas applied in extracorporeal life circulatory
support (ELCS). Chapter 3 focuses on the aim and objectives of the doctoral thesis. The
main aim was to develop an alternative method of LV unloading or LV overload reduction,
which has the potential for reducing the invasiveness of LV unloading during VA-ECMO
therapy. Chapter 4 describes the material and methods, in other words, methodology and
techniques for the collection the data and analysis of archived data. Chapter 5 outlines the
results and discussion. This chapter deals with experimental study with porcine model of CS,
further these data were used for modeling and simulation; describes a novel method to unload
LV during VA-ECMO; explains the investigation of DLAC capacities for LV decompression
during VA-ECMO therapy asses by mathematical modeling and simulation and analyze the
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capability of a DLAC to unload LV during ECMO in porcine model of CS. Summary and
future perspectives are drawn in Chapter 6. The main aim of the doctoral thesis has been
reached. On the basis of the results of conducted studies, it can be concluded that DLAC
presents a promising solution for LV unloading during VA-ECMO, and has the potential for
reducing the invasiveness of LV unloading during VA-ECMO therapy. It is a novel method
to mitigate negative sequelae of VA-ECMO.
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2 State of the art
The purpose of this chapter is to describe ELCS, or ECMO technology, hemodynamic and
cardiac performance parameters in ECMO treated individuals. Furthermore, this chapter
also deals with the advantages and disadvantages of ECMO therapy, and it introduces the
currently existing methods to prevent LV overload of patients on VA-ECMO. Lastly, the
chapter describes the parameters and features of the available peripheral cannulas.
For the literature review, the following databases were used EBSCOhost Research Databases,
IEEE Xplore, ScienceDirect, Scopus, SpringerLink, Wiley Online Library, Critical Care, and
PubMed.
The following words and phrases were used to find the necessary information: ECMO; left
ventricular decompression; cardiogenic shock; left ventricular rest; left ventricular unloading
during VA-ECMO; prevention LV distensions during ECMO therapy; extracorporeal life sup-
port; prevention pulmonary edema during ECMO therapy; ECMO y connector decompres-
sion; cannula dimensions; cannula material; cannula position; complications; extracorporeal
membrane oxygenation; surface coating.
2.1 Extracorporeal membrane oxygenation therapy
ECMO falls under the broader heading of extracorporeal life support [44]. ECMO is a
technology allowing extended support with an acceptable rate of hemolysis and coagulation
impairment. Modern ECMO devices are more and more compact and easy to use, and
they are also optimized for transportation and to facilitate the implantation of the system
wherever the emergency occurs [13].
ECMO leads to circulatory support with the opportunity to oxygenate the blood; it is a
miniaturized and simplified form of cardiopulmonary bypass [78, 82]. The principle of ECMO
is that an external artificial circulator draws a portion of blood outside of the body, through a
cannula and tubing, and after oxygenation (increasing the oxygen level) and decarboxylation
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(CO2 removal) into a gas exchange device (oxygenator), the blood returns to the circulation
via another tubing and cannula [25, 62, 61, 78, 82]. There are two types of ECMO: veno-
venous extracorporeal membrane oxygenation (VV-ECMO) which is typically used for gas
exchange failure (Figure 1), and VA-ECMO which is typically used for circulatory failure
(Figure 2).
Figure 1: Peripheral veno-venous extracorporeal membrane oxygenation. Reprinted with
permission from Maquet Czech Republic s.r.o.
This doctoral thesis deals with ECMO in veno-arterial configuration. ECMO in veno-
arterial configuration provides right atrium-to-aorta circulatory support. The VA-ECMO
circuit consists of a venous inflow cannula (Figure 3), an extracorporeal blood pump, an oxy-
genator, an arterial outflow cannula (Figure 3), and connecting tubes. In minimally invasive
(ie, peripheral) settings, the inflow cannula is usually inserted percutaneously through the
femoral or jugular vein into the right atrium. The deoxygenated venous blood is drawn from
the right atrium and is pumped by a centrifugal pump (Figure 4) to the oxygenator (Figure 5)
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Figure 2: Peripheral veno-arterial extracorporeal membrane oxygenation. Reprinted with
permission from Maquet Czech Republic s.r.o.
herein blood gases are exchanged. Nowadays ECMO pumps are centrifugal; they generate
continuous or pulsatile flow. It was estimated that the electrocardiographic-synchronized pul-
satile ECLS flow preserves LV function in comparison with standard continuous-flow ECLS
in CS [86]. After oxygenation, blood is returned to the aorta via an arterial outflow cannula;
it is usually inserted into the femoral artery, in peripheral settings.
A notable advantage of ECMO is that cannulation may be performed nearly everywhere;
the system and all parts are transportable. ECMO mobility enables the medical team to use
it during transport of patients (Figure 6) [78].
In general, ECMO can be used with different strategies. In patients with severe CS from
myocarditis or myocardial infarction, mechanical support is commonly utilized in a bridge-to-
recovery approach. During the resuscitation of patients, a bridge-to-decision strategy usually
requires ECMO implantation, by the ECMO team, for further therapy [78]. ECMO provides
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Figure 3: A venous inflow cannula (on the left) an arterial outflow cannula (on the right) for
veno-venous and veno-arterial vessel access for ECMO support. Reprinted with permission
from Maquet Czech Republic s.r.o.
Figure 4: A centrifugal pump for extracorporeal membrane oxygenation support. Reprinted
with permission from Maquet Czech Republic s.r.o.
excellent short-term circulation support [5]. Successful ECMO use has been reported in
acute CS, acute decompensation of congestive heart failure, drug intoxication, accidental
hypothermia, and cardiopulmonary resuscitation during CA [41, 85, 68, 122, 44, 62, 61,
34, 9, 107, 52, 50, 11]. Several case series reported the use of VA-ECMO as support for
high-risk percutaneous coronary and valvular intervention [41, 10], arrhythmic storm, or
19
Figure 5: A oxygenator for extracorporeal membrane oxygenation support. CRRT - Continu-
ous renal replacement therapy. Reprinted with permission from Maquet Czech Republic s.r.o.
Figure 6: The portable extracorporeal membrane oxygenation support machine. Reprinted
with permission from Maquet Czech Republic s.r.o.
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electro-anatomical mapping, and catheter ablation of nontolerated ventricular tachycardia
[97]. VA-ECMO has also been successfully used in sepsis-associated cardiomyopathy [43, 92],
pulmonary hypertension [4] and pulmonary embolism [77, 64].
2.2 Hemodynamic and cardiac performance parameters in ECMO
treated individuals with cardiac arrest and cardiogenic shock
VA-ECMO is a powerful life support system, which is increasingly used in the therapy of
critical conditions caused by advanced cardiac pump failure such as severe and rapidly pro-
gressing CS or CA refractory to standard resuscitation techniques [78, 20]. Basic indications
for VA-ECMO are 1) CS, 2) CA [41, 85] 3) myocarditis, 4) patients who cannot be weaned
from cardiopulmonary bypass after cardiac surgery [85].
Cardiogenic shock.
CS is a clinical state which occurs as a result of tissue hypoxia; it is caused by primary
cardiac pathology which leads to inadequate cardiac output (CO) and systemic perfusion in
the presence of adequate intravascular volume [41, 55].
During CS the heart suffers from the ineffectiveness of the cardiac pump function; the
other organs such as the gut, liver, kidneys, and brain are at risk due to insufficient perfusion
(multiorgan dysfunction syndrome). Furthermore, the risk of pneumonia associated with
the occurrence of CS is increased. As a result of reduced coronary perfusion, CO is further
reduced, and multiorgan dysfunction or/and multiorgan abnormalities are complicated by
metabolic acidosis and acute coagulopathy. All these conditions exacerbate each other in a
deadly vicious circle [78].
CS is primarily defined based on hemodynamic parameters. In addition to classical CS
markers - pressure and heart rate (HR), there are additional markers of multiorgan dysfunc-
tion and circulatory disturbance - central venous oxygenation, urine output, liver enzymes,
and serum lactate [78].
There is some variability in the definition of CS in clinical trials [41, 55].
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I. Low blood pressure (<90 mmHg) for at least 1 hour refractory to fluid administration; low
blood pressure (<90 mmHg) caused by cardiac dysfunction; low blood pressure (<90 mmHg)
associated with hypoperfusion or a cardiac index (CI) less than 2.2 L/min/m2 and pulmonary
artery wedge pressure (PAWP) higher than 18 mmHg [41].
II. A decrease of cerebral and tissue oxygenation down to 50 %, increased serum lactate level,
mixed venous oxygen saturation (SvO2) less than 55 %, encephalopathy symptoms, CI lower
than 2.2 liter/min-1/m-2 despite adequate preload, and systemic signs of low CO [85].
III. A pathological state with the most common cut-off points for systolic blood pressure
(SBP) less than 80-90 mmHg for≥30 min and a significantly decreased CI (<1.8 liters/minute/m2
without support or<2.0 liters/minute/m2 with support), elevated serum lactate (≥2 mmol/liter)
[41, 55].
In patients with CS, as a result of hypoperfusion of the myocardium and peripheral
organs, the process of anaerobic metabolism in the tissues of organs begins, which may lead
to lactic acidosis. The accumulation of lactic acid can lead to swelling of mitochondria and
degeneration, causing glycogen depletion, which in turn may worsen the function of the
myocardium and suppress glycolysis, which leads to an irreversible ischemic lesion. Serum
lactate level is an important predictor of CS. A lactate level > 6.5 mmol/L in CS patients is
a very strong independent prognostic factor of mortality [41].
Clinical signs indicative of CS include signs of systemic hypoperfusion, such as cold skin,
and/or oliguria, elevated jugular venous pressure, altered mental state. Rales, indicating
pulmonary edema, may or may not be present. Neither auscultation nor chest radiograph
detects pulmonary edema in 30 % of patients with CS. CS can occur as a result of a wide
variety of cardiac disorders, including acute coronary syndrome, valvular disease, myocardial
and/or pericardial disease, congenital lesions, or mechanical injuries of the heart [41, 55].
In patients with severe CS, ECMO is routinely employed [78]. ECMO in CS is used to
achieve the following goals:
• To stabilize hemodynamics and to improve the tissue perfusion of end organs functions.
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• To limit LV wall stress; consequently, reducing myocardial oxygen demand.
• To improve coronary perfusion.
• To gain time for:
– Complete revascularization.
– Comprehensive assessment (Neoro, Surgical, or Adv HF) [20].
• As a bridge to:
– Recovery.
– Decision (percutaneous coronary intervention, elimination of ventricular tachycar-
dia, percutaneous or surgical elimination of critical valve defect, and other heart
surgery).
– Intervention.
– Left ventricular assist device implantation.
– Heart transplantation [85].
Cardiac arrest.
CA is a major cause of unexpected death in developed countries with a low probability
of patient survival [31]. CA refractory to standard resuscitation techniques is an emerging
indication for mechanical circulatory support [78]. The survival of patients, who have suffered
in-hospital or out-of-hospital CA, depends on several factors, such as the time of recognition
of the CA, time of initiation of cardiopulmonary resuscitation, time of the first fibrillation and
rhythm presentation [31]. Out-of-hospital CA occurs with an estimated incidence of 500,000
per year in Europe, with two-thirds having a primary cardiac cause. Despite interventional
therapy and modern intensive care, mortality after out-of-hospital CA remains high [78].
The urgent initiation of cardiopulmonary resuscitation right after an collapse and the
availability of automated external defibrillators is an essential factor in increasing the proba-
bility of survival of the person who has suffered CA. The first electric shock should be applied
as soon as possible in order to minimize the time of hypoperfusion and hasten the return of
spontaneous circulation in selected patients; therefore to prevent failure of the LV and the
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development of CS. The CA results in myocardial and end organs ischemia, which leads to
acidosis, an adverse metabolic, and vasoplegia. Cardiac hypoperfusion results in an inability
of the heart to respond to the needs of circulation, which is enhanced peripheral ischemia.
After the return of spontaneous circulation, the restoration of system perfusion is significant
in order to reduce multiorgan dysfunction. Complete cardiac revascularization is strongly
recommended in selected patients after CA, but it is important to care for other end organs
such as the kidneys, the liver, the intestines, and the brain [78]. CA refractory to standard
resuscitation techniques is an indicator of the purpose of ECMO; it’s prescription is useful
when the laboratory tests indicate lactate less than 21 mmol/L, pH more than 6.7, SvO2
more than 8 % [85].
2.3 Left ventricular overload during VA-ECMO therapy
Notwithstanding the fact that ECMO has many advantages, such as the fast set-up of the
system and efficient hemodynamic support [78]; it also has a significant risk of complications.
An important pitfall of the ECMO, which can highly impair patient outcome, is inappropriate
LV unloading. VA-ECMO can cause LV overload, primarily due to the increased afterload
(Figure 7) [78, 44, 13, 9].
It should be recognized that the overload of LV during VA-ECMO is estimated in about
70 % of cases and can significantly affect the survival of patients [24]. In the presence of severe
LV dysfunction, the LV is unable to eject a sufficient volume of blood against the increased
afterload caused by the ECMO [41, 68, 44, 13, 34, 9, 50, 112, 87, 99]. The measure of the
reduction in LV stroke volume (SV) is dependent on the degree of the contractile function
violation, the presence of mitral/aortic regurgitation, and the magnitude of extracorporeal
blood flow (EBF) [61, 87].
Simulation [86], animal [87], and human [6] studies show unsatisfactory LV unloading
during high-flow VA-ECMO, which impairs several parameters of LV performance. In pa-
tients with extremely low systolic LV function the aortic valve can remain closed even during
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Figure 7: Left ventricular overload in consequence of the VA-ECMO application
systole [111, 78, 73]. The extreme LV overload significantly deteriorates the ventricular con-
tractile function, which causes stagnation of blood in the LV, making the left heart chamber
a favorable environment for the formation of thrombus. This event has been demonstrated
during experiments with animal models and has been confirmed in human studies [73]. The
inappropriate LV unloading potentially results in increased LV filling pressures, severe LV
distension, increased wall stress, severe pulmonary congestion, and pulmonary edema, in-
creased myocardial oxygen consumption [68, 107, 52, 87, 6, 32], despite a reduction of preload
[73, 78, 44, 13, 9] and the presence of sufficient systemic circulation [78]. If the CS has occurred
as a result of decompensation in chronic heart failure, the LV is likely to be compliant and the
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mitral valve is frequently incompetent as a result of chronic annular dilation and mitral valve
leaflet tethering. The resultant mitral reflux would decompress the LV to some extent but may
result in elevation of left atrial pressure and pulmonary edema [68, 13, 61, 107, 32, 21, 103].
In contrast, in acute CS, such as following acute myocarditis or myocardial infarction, the
LV is likely to be noncompliant and the mitral valve likely to be competent. LV distension in
this setting will result in a significant rise in intraventricular pressure and wall tension, which
could be detrimental to damaged myocardium. In addition, the rise in LV pressure could
reduce coronary blood flow, causing myocardial ischemia, particularly in the subendocardial
area [50, 107, 120]. The development of LV overload and distension could also be potentiated
by the presence of aortic regurgitation [104]. Increased LV afterload, together with severe
systolic dysfunction, may result in LV overload and can lead to refractory pulmonary edema,
fatal pulmonary hemorrhage, and LV clotting [21, 111, 61]. LV overload during VA-ECMO
therapy represents a critical condition that frequently requires urgent intervention to unload
the LV; LV unloading is a crucial issue during VA-ECMO.
2.4 The methods of left ventricular unloading during VA-ECMO
therapy
ECMO can increase LV afterload and may result in LV loading. These negative sequelae of
VA-ECMO can be prevented and resolved by LV venting or active LV unloading [78, 8]. It
has been shown that early decompression is associated with reduced time on ECMO and the
reduction of ECMO-associated complications [38]. To date, several approaches have been
proposed to unload an overloaded LV during VA-ECMO therapy.
Atrial septostomy.
LV decompression can be achieved by creating left atrial and right atrial communication -
a septal defect or patent foramen ovale; whereas, it is widely known that, left-sided filling
pressure is higher than right-sided filling pressures in the heart. The favorable effect of such a
left-to-right shunt on LV decompression has been reported in children and adults [24]. Atrial
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shunt can be created artificially with percutaneous blade or balloon septostomy [52, 103].
Seib et al. [103] reported series of 10 patients with severe LV dysfunction (seven myocarditis,
three dilated cardiomyopathy) who required circulatory support with ECMO and who under-
went left heart decompression with blade and balloon atrial septostomy (BBAS). BBAS was
performed prior to initiating ECMO in three patients and during ECMO in seven patients.
A femoral venous approach was used in all patients. Transseptal puncture was required in
nine patients while one patient had a patent foramen ovale. The procedure was successful
in all patients and led to LV decompression and pulmonary decongestion. Left atrial mean
pressure fell from a mean of 30.5 mmHg to 16 mmHg. Left atrial to right atrial pressure
gradient fell from a mean of 20 mmHg pre-BBAS to 3 mmHg post-BBAS. Artificial atrial
septal defect size ranged from 2.5 mm to 8 mm [103]. It should be realized that atrial sep-
tostomy has been reported as one of the first LV unloading techniques during VA-ECMO
but remains technically demanding, limited efficacy, and experience is largely confined to
specialized centers and pediatric patients [24].
Left atrial venting.
Unloading can be achieved by placement of an additional draining cannula through the atrial
septum. With guidance by bedside transoesophageal echocardiography, a percutaneous atrial
transseptal cannula can be placed and connected to the venous site of the ECMO circuit
[24, 112, 7]. Swartz et al. [112] reported a case involving a 13-year-old girl who presented with
CS. VA-ECMO was initiated, but after six days, severe LV distension resulted in decreased
VA-ECMO flows. With guidance by bedside transesophageal echocardiography, a percuta-
neous atrial transseptal cannula was placed and connected to the venous site of the ECMO
circuit, thus decompressing the LV. The patient improved, was weaned from VA-ECMO five
days later and was discharged from the hospital [112]. Aiyagari et al. [7] described a se-
ries of seven patients with cardiac failure on VA-ECMO with left atrial hypertension. All
patients underwent left atrial decompression with transseptal puncture and placement of a
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drain (from 8 Fr1 to 15 Fr). The average time from ECMO cannulation to left atrial de-
compression was 11 hours. The average initial left atrial pressure was 31 mmHg. Successful
drain placement was achieved in all patients with no major periprocedural complications.
Echocardiographic improvement in left atrial dilation was achieved in five (71 %) patients.
Inability to decompress the left atrium was fatal in two patients. Four (57 %) patients were
decannulated and three (43 %) survived to hospital discharge [7].
LV venting.
The LV can be vented directly by placing a transaortic vent through the axillary artery or
by echocardiography-guided insertion of a pigtail catheter into the LV through the aortic
valve and connected to the venous site of the ECMO circuit [78, 35, 13]. Fumagalli et al.
[35] reported a case in which extracorporeal life support was used as a bridge to heart trans-
plantation, for a patient with CS. LV decompression, during ECMO, was achieved with a
catheter placed percutaneously through the aortic valve into the LV. The blood from the
LV was drained following the normalization of left heart filling pressures. The catheter ap-
plication led to the resolution of the patient’s pulmonary edema. Subsequently, the patient
underwent successful heart transplantation, and then the patient underwent mechanical cir-
culatory support for a further seven days [35]. Barbone et al. [13] proposed LV unloading
with a 7 Fr pigtail catheter inserted into the LV via the femoral artery contralateral to the
arterial outflow cannula. This approach was used in three patients with CS due to acute
myocardial infarction. As a result of pigtail catheter application, the resolution of LV dis-
tension and prevention of lung congestion without major complications were achieved in all
three cases.
Pulmonary artery drainage.
One of the approaches for LV decompression is the percutaneous insertion of the second ve-
nous cannula into the pulmonary artery and connection of this cannula to the venous site of
the ECMO circuit [11, 32]. Avali et al. [11] reported a case involving a 43-year-old woman
1The French scale (Fr) is a system which is commonly used to measure the diameter of a cannula or
catheter; 1 Fr=1/3 mm
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treated with ECMO for refractory CS after left pneumonia and severe sepsis. A 15 Fr venous
cannula was placed percutaneously to the pulmonary artery and connected to the ECMO
circuit to decompress the left heart, and to facilitate LV function. After myocardial recovery,
the patient was weaned and ECMO was removed on day sixteen [11]. Fouilloux et al. [32]
described unloading of the LV with a cannula inserted into the pulmonary trunk through the
inferior vena cava with a femoral approach in a two-year-old girl with restrictive cardiomy-
opathy. A few hours later, the chest X-ray improved and five days later, recovery of the LV
function allowed removal of the pulmonary artery cannula [32].
Intra-aortic balloon pump.
Intra-aortic balloon pump (IABP) counterpulsation is a device that inflates and deflates a
30 cm to 50 cm balloon in the descending aorta. The balloon inflations and deflations are
synchronized with the cardiac cycle and, therefore, deflation just before systolic ejection may
decrease afterload and improve LV ejection. Moreover, increased diastolic pressure on IABP
could also improve coronary blood flow. Despite the controversial data from the Intraaortic
Balloon Pump in cardiogenic SHOCK (IABP-SHOCK) II trial [114], IABP currently remains
one of the most commonly used mechanical circulatory support devices in the treatment of
acute heart failure. When administered in a timely manner, it can play a critical role in
the rescue of patients with acute myocardial damage. It has been shown in animal models
that insertion of IABP during VA-ECMO support may improve several parameters of LV
performance [99]. Currently, several centers use IABP to reduce LV afterload during VA-
ECMO therapy. In a group of 219 patients treated with VA-ECMO after cardiac surgery,
Doll et al. [23] found that the use of IABP during ECMO support was associated with a
significantly higher survival rate. Ma et al. [62] reported 54 adult patients with acute heart
failure who received combined ECMO and IABP support, all of whom showed improvements
in terms of overall circulation. Thirty-four of the patients were successfully weaned from
mechanical circulatory support, and 21 (39 %) survived to hospital discharge [62]. The
study by Petroni et al. [92] showed that adding an IABP to peripheral VA-ECMO was as-
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sociated with improved LV function. Discontinuation of intra-aortic balloon pumping was
associated with higher PAWP (19±10 mmHg versus 15±8 mmHg; P=0.01), increased LV
end-systolic (51±13 mmHg versus 50±14 mmHg; P=0.05) and end-diastolic (55±13 mmHg
versus 52±14 mmHg; P=0.003) diameters, and decreased pulse pressure (15±13 mmHg ver-
sus 29±22 mmHg; P=0.02) [92]. In contrast, Park et al. [91] did not find any mortality or
morbidity benefit with IABP in the group of 96 VA-ECMO-treated patients with CS due
to acute myocardial infarction. Recent clinical data provide conflicting evidence and partly
contradict this picture of post-cardiotomy failure and infarct-related shock. There are ex-
tensive analyses that do not unequivocally support the routine combination of VA-ECMO
and IABP as a clinical standard, whereas another recent analysis favors its application and
suggests a survival benefit. The IABP may also have a negative impact on the spinal cord
and cerebral blood flow during VA-ECMO, especially when the native cardiac function is
severely impaired [24].
Percutaneous LV support devices.
Percutaneously inserted pumps have been developed to drain the LV and eject blood from
LV into the ascending aorta [78]. Impella LP 2.5 (Abiomed Inc, USA) is a catheter-based
transaortic microaxial flow pump that can be introduced through a percutaneous femoral
approach. The device is placed across the aortic valve and pumps up to 2.5 L/min of blood
from the LV into the ascending aorta. The Impella 2.5 has been reported as an adjunct to
peripheral VA-ECMO in order to unload the LV representing the second largest clinical ex-
perience as LV unloading intervention during VA-ECMO following the IABP [24]. Koeckert
et al. [50] reported the use of Impella LP 2.5 for LV decompression in a 70-year-old man with
decompensated heart failure who was placed on VA-ECMO for a CS with severe pulmonary
edema and respiratory failure. Both devices were successfully weaned on day 5 after my-
ocardial recovery [50]. Narain et al. [81] described a case involving a 31-year-old man with
fulminant myocarditis treated with the Impella device and VA-ECMO. On full mechanical
circulatory support, the hemodynamic status improved and both systems were explanted
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after 48 hours [81]. Modern Impella CP is abble to increase CO by up to 3.5 L/min [71];
the Impella 5.0 provides up to 5 L/min [36]. The increasing survival rate was reported the
in patients with CA and CS with the Impella CP [117] and with the Impella 5.0 [36]. The
Impella device should, therefore, be considered as a powerful LV unloading device during
VA-ECMO [24]. Nonetheless, several studies reported that the application of Impella can
leads to significant hemolysis [12, 83] .
Various methods for left heart decompression are known, but there is no consensus about
the appropriate method and timing of decompression [21]. Until the present time, all of the
methods currently in use requires further intervention; this increases the invasiveness and
thus can lead to additional complications.
Therefore, the development of an alternative less-invasive method of left heart unloading
is a significant issue in VA-ECMO therapy.
2.5 Peripheral cannulas in extracorporeal life support
As outlined earlier, each of the currently reported methods for LV unloading during ECMO
require further intervention, which increases the invasiveness of the ECMO therapy and thus
can lead to additional complications such as an infection, bleeding and prolonged recovery
times. An alternative and novel less-traumatic method to prevent LV overload during ECMO
is to modify the configuration of the arterial reinfusion peripheral cannula.
ECMO cannulas are used to provide the interface between the patient and the extracor-
poreal circuit. Cannulas in ECLS devices are used in many forms for direct cannulation,
peripheral cannulation, venous cannula, an arterial cannula, for adults and children. They
are used in open surgery, laparoscopic surgery, and in different interventions. The emergency
use of ECMO usually requires percutaneous cannulation of the femoral vessels [72]. The
main advantage of peripheral cannulation is that it does not require open chest surgery for
initiation of ECMO [49, 44]. The peripheral ECMO cannulas provide greater versatility for
cannulation techniques and facilitate working towards striving for smaller incisions.
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2.5.1 Types of peripheral cannulas
There are several types of modern peripheral cannulas that are used in practice.
Single-lumen peripheral cannulas.
Single-lumen peripheral cannulas are used to provide venous and arterial access for VA-
ECMO or multiple site venous access for VV-ECMO [100, 74, 58, 56]. The deoxygenated
blood is drained through an inflow cannula. The oxygenated blood is returned via an outflow
cannula [17] (Figure 8).
Figure 8: Percutaneous arterial cannula (on the left) and percutaneous venous cannula (on
the right)
Basically, a single-lumen peripheral cannula is an elastic tube with an orifice at the tip
[58, 3] and side holes; it has been shown that the side holes decrease the mechanical stress
on blood components [51].
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The alternative type of single-lumen peripheral cannula is a Smartcanula (Smartcanula®,
Smartcanula LLC, Lausanne, Switzerland) (Figure 9). It has a wire structure and is a
virtually wall-less device, in contrast with the current design of percutaneous cannulas. It
is a virtually wall-less cannula with an open wall (mesh structure) which allows collapsed
insertion and expansion in situ [3, 15]. The design of Smartcanula allows a decrease in the
pressure drop throughout the cannula; thereby, increasing the EBF.
Figure 9: Smartcanula. T - tubing, C - covered, U – uncovered
Double-lumen peripheral cannulas.
Double-lumen cannulas combine both drainage and reinfusion lumens into one cannula [51]
(Figure 10). This type of cannula is less-invasive and provides veno-venous support via
a single jugular venous access site [58]. The right jugular vein cannulation has a much
shorter route to the right atrium than femoral cannulation. It can accommodate a much
larger cannula for higher performance [22]. Using this type of cannula reduces the circuit
size, which minimizes blood cells and circuit interaction. Nevertheless, the cannula size is
much larger than that of the standard peripheral cannula and it is not very elastic which
complicates the double-lumen cannulas admission [22, 49]. If the fluoroscopy is not available,
the insertion of the double-lumen cannula is not recommended, because of the risk of right
ventricular perforation [49].
2.5.2 Cannula position
In the veno-arterial configuration of ECMO, an inflow peripheral cannula is inserted via the
femoral vein or via the right internal jugular vein with its tip in the right atrium. The outflow
cannula is inserted via the femoral artery with the tip position in the iliac artery or in the
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Figure 10: Double-lumen cannula
distal abdominal aorta. Another approach of an inflow peripheral cannula insertion is via the
subclavian artery with the tip position into the ascending aorta [41, 44, 25, 21, 72, 63, 14].
In the veno-venous configuration of ECMO, the peripheral cannulas are usually introduced
via the femoral and jugular veins with the cannula tips at the border between the right
atrium and the superior and inferior caval veins to minimize recirculation [80]. In the case
of using a double-lumen cannula, the right-sided jugular vein is commonly used for insertion
[44, 60, 63, 79].
2.5.3 Material
Modern cannulas are of a strong, one-piece polyurethane molding construction. The cannulas
are manufactured from biocompatible silicone polyurethane polymer, which may be coated
with polymers that may reduce platelet activation and the inflammatory response at the
blood-cannula interface. Cannulas combine flexibility and resistance, e.g. polyurethane has
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high material strength at room temperature and becomes more malleable at body tempera-
ture (this aids the insertion of the cannula) [51, 58, 14].
The cannulas are constructed with reinforced stainless steel (SS) wire. Wire reinforcement
of the cannula walls is used to prevent kinking or collapse [51, 58, 1]. This type of design
provides a longer-term ambulatory application [22]. The cannulas that were manufactured
from non-wire-reinforced polyurethane became deformed following insertion. Kinking and
collapse of the cannula can lead to catastrophic interruption of the flow of ECMO [58].
A rigid cannula introducer is made of polyvinylchloride with an embedded SS rod [22].
2.5.4 Surface coating
Although modern cannulas are made of biocompatible materials, surface coatings are applied
on the cannula to reduce the activation of the clotting; control of blood clotting is essential
during extracorporeal life support [51, 14].
Currently, the trend is to prevent blood clotting without using anticoagulants [2]. Heparin-
coated surfaces result in reduced complement and inflammatory activation due to its anti-
inflammatory properties. Nevertheless, heparin causes the development of osteopenia and
thrombocytopenia [51, 123]. Heparin-coated surfaces can trigger release of cytokines, which
exert a damaging effect on the lungs [98]. Furthermore, heparin-based coatings can leach into
the blood and result in the exposure of the blood to extremely high heparin doses (> 50 U/kg)
[59]. This can cause excessive bleeding and can be lethal.
Nowadays biocompatible surfaces more closely resemble the physiological endothelium.
The coatings have a hydrophilic outer layer and some contain negatively charged groups
to repel negatively charged proteins and platelets and thereby create a layer between the
components of human blood and the artificial surface. For example, “Balance Biosurface”
by Medtronic and “X Coating” by Terumo [51].
An alternative coating material for ECLS cannulas is bivalirudin (BVLD). BVLD is a
short, synthetic peptide, derived from hirudin, that is potent, highly specific and a reversible
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thrombin inhibitor which is used as a surface coating. It was reported that BVLD was
covalently conjugated on plasma polymerized allylamine (PPAam) coated 316L SS to develop
an anticoagulant surface. The BVLD-PPAam-modified 316L SS disk was implanted in the
femoral artery of dogs for 5 weeks. The anticoagulant surface prevented thrombosis formation
by rapidly growing a homogeneous and intact endothelium on its surface [51, 123].
The next nonheparin coating is tethered-liquid perfluorocarbon (TLP). The TLP resisted
adhesion of fibrin and platelets, suppressed biofouling and reduced thrombosis and bacterial
adhesion. Medical materials with a TLP coating have antithrombogenic and anti-biofouling
surfaces that do not require co-administration of antiplatelet, anticoagulant or antibiotic
medications. It was reported that the TLP-coated tubing and catheters in large blood vessels
in pigs retained their ability to prevent occlusive thrombus formation for 8 hours without
using blood thinners such as heparin [2, 59].
2.5.5 Dimensions
The size and location of the inflow and outflow cannulas impact tissue oxygenation as well
as the degree of cardiac support provided. The intent of appropriate cannula choice is to
provide full flow without damaging the cells, particularly erythrocytes, from excessive shear
stress and turbulence [44]. The currently used peripheral ECLS cannulas for adults typically
range from 18 Fr to 29 Fr for venous and 13–23 Fr for arterial cannulas [44, 14, 65]. The
double-lumen cannula sizes for adults are from 13 Fr to 31 Fr for Avalon Elite Bi-Caval Dual
Lumen Catheters [66] and from 13 Fr to 32 Fr for OriGen dual lumen catheters [84].
For adult patients, the cannula length is variable and may range from 50 cm for inflow
and from 18 cm for outflow cannulas depending upon the manufacturer, the anatomy of
the patient and the vasculature [14]. The insertion length of peripheral cannulas for adults
may vary in range from 38 cm to 55 cm for inflow and from 15 cm to 23 cm for outflow
cannulas [65]. For double-lumen cannulas, Avalon Elite Bi-Caval Dual Lumen Catheters, the
insertable length range is from 11 cm to 31 cm [66]. The insertable length of OriGen dual
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lumen catheters is from 8 cm to 25 cm [84].
By minimizing the cannula thickness, the internal diameter increases, thereby obtaining
the highest flow efficiency and cannula flexibility with the smallest anatomical footprint [22,
45]. Nowadays, the ultrathin wall of percutaneous cannula achieves a thickness of 0.48 mm
for adult cannulas and 0.38 mm for pediatric cannulas [75]. Double-lumen cannula for VV-
ECMO has a wall thickness of 0.7 mm with a thin membrane sleeve of the infusion lumen
inside the main body with a wall thickness of 0.3 mm [22].
There are a lot of opinions regarding recommendations for cannula size. The increasing
in cannula size decreases the resistance of the cannula; nevertheless, it increases the risk of
vessel damage. The size of the cannula is recommended depending on the patient’s anatomic
features and the weight or body surface area [14, 17, 37]. Depending on the patient’s anatom-
ical parameters, the cannula should reach from the peripheral insertion point to a central
location. Some data suggest that the cannula size should be determined in relation to the
actual size of the vessel [14, 37, 58, 51]. Nevertheless, because many different cannulas exist,
studying the flow chart of each cannula is commonly used to determine the appropriate size
[76]. The cannula provides a resistance within the ECMO circuit and, therefore, creates a
pressure drop (the difference between the pressure entering the cannula and that of leaving)
across it [60]. The pressure-flow characteristics of cannulas are dependent on their length
and internal diameter [113]. The widest and shortest possible cannula is the best choice to
achieve the maximum flow.
Pressure drop versus flow charts of the outflow and inflow cannulas from the manufacturers
is based on evaluations using water as the testing solution [95] at ambient temperature. The
blood flow in the circuit during ECMO may vary depending on blood viscosity, the patient’s
anatomy, and circuit configuration. Blood flow regulated over time to meet physiological
goals such as the stabilization of systemic perfusion and improving end organ functions.
With a higher pressure across the cannula, there is an increase in jetting at the tip, that can
cause intimal damage to the vessel [60]. The high-pressure flow becomes turbulent [51] and
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may damage the red blood cells. In addition, it can be the cause of microbubbles [85] and
induce bubble emboli. The accepted limit of venous cannula pressure drop is 100 mmHg. This
should not ordinarily be exceeded [60]. Newetheles, in the arterial cannula, greater pressure
drop values are allowed. In conclusion, the largest possible cannula can be recommended
to maximize blood flow. Nonetheless, small cannulas provide support by reducing bleeding
complications [113], the risk of vascular damage, ischemia, and obstruction of arteries [85].
2.6 Conclusions
CS and CA share many pathophysiological features, and in this context, VA-ECMO is a
powerful circulatory support system. ECMO is an effective tool for systemic circulation
support and provides gas exchange. However, especially in patients with most severe heart
dysfunction, initiation of VA-ECMO may be associated with LV overload with all of its
consequences including severe pulmonary edema and respiratory failure. VA-ECMO might
increases LV afterload and may result in LV distension, and pulmonary edema, which can be
prevented and resolved by LV venting or active LV unloading.
To date, various techniques have been proposed to decrease LV distension and improve its
function during ECMO therapy. However, each of these methods increases the invasiveness
of the procedure; the additional interventions, which are required by currently used methods
for LV unloading during ECMO, increase the risk of complications such as infection, bleeding
and longer recovery times.
An alternative method to prevent LV overload during ECMO is to modify the configura-
tion of the arterial reinfusion peripheral cannula. Today’s peripheral cannula has a one-piece,
biocompatible, thin-walled, kink resistant, wire-wound body. The construction of modern
cannulas maximizes flow rates and flexibility.
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3 Aims and objectives
This doctoral thesis aims to develop an alternative method of LV unloading or LV overload
reduction, which has the potential for reducing the invasiveness of LV unloading during
VA-ECMO therapy. It is intended that the findings will contribute to the mitigation of
ECMO complications such as LV overload; furthermore, it is intended to help eliminate the
complications, of the current methods for LV decompression, such as an additional source of
bleeding, infection, and the longer recovery times of ECMO treated patients.
This aim leads to the following core doctoral thesis objectives:
1. To describe hemodynamic and cardiac performance parameters in ECMO treated in-
dividuals with CA and CS.
2. To describe currently existing methods for LV unloading in VA-ECMO treated individ-
uals.
3. To investigate the impact of ECMO therapy on LV performance in large animal models
of CS.
4. To propose an alternative method of LV unloading or LV overload reduction, which has
the potential for reducing the invasiveness of LV unloading during VA-ECMO therapy.
5. To create a model, based on data from large animal models of CS, and establish the
value of LV decompression by using the proposed alternative method of LV unloading.
6. Based on the modeling and simulation, to identify circumstances under which to in-
crease the value of LV decompression by using the proposed alternative method of LV
unloading.
7. To investigate the impact of the proposed alternative method of LV unloading during
VA-ECMO on LV performance in large animal models of CS.
The long-term goal of the research is to manufacture the proposed invention and involve it
in medical practice.
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4 Material and methods
In this chapter material and methods for modeling, simulation, and experimental study with
models of CS, described in the doctoral thesis, are presented. Swine (Sus scrofa domestica)
with an average weight of forty-five kilograms were used as the experimental animals. The
drafts of DLAC for ECMO were created in AutoCAD software. Modeling and simulations
have been implemented using the Modelica modeling language (Modelica Association) in the
Dymola (Dassault Systemes) modeling environment and using the components from Physi-
olibrary 2.3.1. The data were analyzed by using GraphPad Prism 5.0 software (GraphPad,
USA) and R 3.5.3 software (The R Foundation, Vienna, Austria).
4.1 Experimental study with large animal models
The experimental study was approved by the Charles University 1st Medical School Insti-
tutional Animal Care and Use Committee and was performed at the Animal Laboratory,
Department of Physiology, 1st Medical School, Charles University in Prague and Na Ho-
molce Hospital, Prague, Czech Republic, in accordance with Act No 246/1992 Coll. on the
protection of animals against cruelty. The investigation conforms to the Guide for the Care
and Use of Laboratory Animals published by the US National Institutes of Health (NIH
Publication No. 85-23, revised 1985). Animals were subjected to VA-ECMO implantation
under general anesthesia and artificial ventilation (Figure 11). Subsequently, LV dysfunction
was induced to result in acute severe CS followed by signs of tissue hypoxia. Hemodynamic
and cardiac performance parameters were then measured and processed.
4.1.1 Animal model
The structure and function of the swine, such as size, coronary artery distribution, feeding
patterns, tidal volumes digestive physiology, respiratory rates, dietary habits, propensity to
obesity, kidney structure and function, pulmonary vascular bed structure are similar to hu-
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Figure 11: Animal Laboratory, Department of Physiology, 1st Medical School, Charles Uni-
versity in Prague and Na Homolce Hospital with a large animal model of cardiogenic shock
man structure and function. These facts make pigs good models for the research. Pigs have
been successfully used as models for the evaluation of alcoholism, septic shock, diabetes, der-
mal healing, absorption process, digestion process, osteochondrosis, total parenteral nutrition
process, reflux nephropathy, organ transplantation, obstructive nephropathy, atherosclerosis,
exercise, gingivitis, hypertension, melanoma, and hemorrhagic hypotension [102].
The porcine cardiovascular system is similar to the human cardiovascular system in size,
structure, and functionality; this provides a comparable model in cardiovascular studies such
as the investigation of cardiovascular physiology and pathophysiology, human coronary artery
pathology, recording and analysis of responses to tests of cardiac function, the ventricular
function and hemodynamic vascular parameters indication [101], the development of an im-
proved diagnostic and surgical procedure [102], the modernization of clinical methods and
techniques [101].
Blood gases, pH, circulating blood volume (67.3±3.7 ml/kg in a swine, 69.1±6.6 ml/kg
in a human) and plasma volume (49.6±3.1 ml/kg in a swine, 41.1±4.3 ml/kg in a human)
are similar in a swine and that of man; although swine hematocrit (27±3 % in a swine,
46±5 % in a human) and hemoglobin (8.5±0.8 g/dl in a swine, 15±2 g/dl in a human) are
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slightly lower. The CO of swine is higher than in humans (147±22 ml/min/kg in a swine,
93±20 ml/min/kg in a human), which is associated with an increase in HR (105±10 b/min
in a swine, 70±14 b/min in a human) and SV. Systemic pressure (systolic pressure 127±8
mmHg in a swine, 126±14 mmHg in a human, diastolic pressure 86±7 mmHg in a swine,
79±10 mmHg in a human) and pulmonary pressure (mean pulmonary artery pressure 16±4
mmHg in a swine, 16±2 mmHg in a human) of swine is well in line with human pressure; the
development of pressure is the main factor determining the cardiac work, so the relationship
between swine and human cardiac metabolism and coronary blood flow is also quite similar
[101].
Female swine (Sus scrofa domestica) were used in the experiments. The age of animals was
four to five month; the average body weight was forty-five kilograms. For induction of general
anesthesia, intramuscular administration of midazolam (0.3 mg/kg) in combination with ke-
tamine hydrochloride (15–20 mg/kg) were used. Intravenous boluses of propofol (2 mg/kg)
and morphine (0.1–0.2 mg/kg) were administered to initiate the anesthesia; followed by
orotracheal intubation of the animals. The maintenance of anesthesia was achieved by a con-
tinuous intravenous infusion of propofol (8–10 mg/kg/h) and morphine (0.1–0.2 mg/kg/h);
the doses were titrated, taking into account physiological parameters, photoreaction, corneal
and palpebral reflexes, lacrimation and spontaneous movement. The animals were eutha-
nized after the experimental studies by the injection of potassium chloride (2 mEq/kg), in
combination with general anesthesia [87, 88, 93].
Multiple sheath insertions were performed using bilateral femoral (arterial and venous)
and jugular approaches; the Seldinger insertion method was used to obtain access to ves-
sels. An unfractionated heparin bolus (100 U/kg) was administered intravenously to prevent
thrombosis, especially at the site of sheath insertion. The activated clotting time was main-
tained at 180–250 s, during experiments; to ensure this condition, heparin was administered
intravenously continuously; the infusion rate was 50 U/kg/h. Values of activated clotting
times were monitored every hour using the Hemochron Junior + Microcoagulation System
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(ITC, USA). Animals were orotracheal intubated, during experiments. A Hamilton G5 ven-
tilator was used for mechanical ventilation (Hamilton Medical AG, Switzerland); the mode
INTELLiVENT—Adaptive Support Ventilation was set. The mechanical ventilator was set
to keep an oxygen saturation (SpO2) of 95–99 %, and an end-tidal CO2 pressure of 4.8–5.6 kPa
[87, 86, 88].
4.1.2 ECMO system
Intubated animals underwent VA-ECMO implantation. For the purposes of experimental
research Levitronix Centri-mag (Thoratec, USA); nonpulsatile centrifugal pump; tubing set
with Quadrox membrane oxygenator with Softline Coating (MAQUET Cardiopulmonary
AG, Germany); and a mechanical gas blender (Sechrist, USA) have been used. The periph-
eral cannulas were inserted into a femoral artery and femoral vein, after repeated dilatation,
by using a standard Seldinger technique. Under ultrasound guidance, the larger diameter
left or right femoral veins were used for venous cannula insertion. For the insertion of arte-
rial cannulae, the same procedure for femoral artery selection was used. The tip of venous
cannulas was positioned at the cava-right atrial junction; the position of the tip was verified
using fluoroscopy. The sizes of the cannulas were 15 Fr for the arterial cannula, 23 Fr for the
prototype of the DLAC, and 21 Fr for the venous cannula. Blood gases in the arterial site of
the ECMO circuit (in the blood which living the oxygenator) were continuously detected by
CDITM Blood Parameter Monitoring System 500, Terumo Cardiovascular Systems Corpora-
tion, USA) [87, 88, 93, 93]. The oxygen/air ratio and flow were adjusted, by the gas blender,
to maintain pO2 in the ranges of 10–15 kPa and pCO2 in the ranges of 4.0–6.5 kPa in the
blood which live the oxygenator. The extracorporeal flow was maintained at 1 L/min prior
to the start of the measurements.
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4.1.3 The double lumen arterial cannula prototype
The prototype of the DLAC (Figure 14) was fabricated from existing components, which are
available on the market. The DLAC prototype was created by using a 23 Fr Avalon Elite
double-lumen venous cannula (MAQUET Cardiopulmonary GmbH, Germany) (Figure 12)
and of 10 Fr pigtail catheter (Cook Ireland Ltd., Ireland) (Figure 13).
Figure 12: Avalon Elite double-lumen venous cannula
The 10 Fr pigtail catheter was inserted through the drainage lumen of a double-lumen
venous cannula (Figure 15). The catheter was connected to the venous site of ECMO circuit
by the connector with a lateral luer exit. The length of the pigtail catheter was 350 cm,
therefore it was cut to 120 cm; this length is enough to reach from the insertion point (the
femoral artery) to the LV in both the porcine mode and an adult person.
The reinfusion lumen of a double-lumen venous cannula served to return the oxygenated
blood to the circulation, whereas the pigtail catheter, inserted through the drainage lumen
of a double-lumen venous cannula, was used solely for LV unloading.
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Figure 13: Pigtail catheter
Figure 14: The prototype of double lumen arterial cannula
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Figure 15: The embodiment of the double lumen arterial cannula prototype
4.1.4 The induction of cardiogenic shock
Induction of CS was attained within coronary arteries blood hypoxemia. The largest left
main coronary artery branch (left anterior descending artery or left circumflex artery) was
indicated in each animal; coronary angiography was used for this purpose. Then, guide
wires were placed precisely in this vessel. The first guide wire was used for the introduction
of a balloon catheter. The second guide wire was used for the introduction of an over-
the-wire export catheter (Medtronic, USA). The tip of the over-the-wire export catheter
was positioned distal to the end of a balloon. A proximal end of the export catheter was
connected to the venous site of the ECMO circuit, between the ECMO pump end oxygenator
(Figure 16). After inflation of the balloon in the vessel, the coronary artery branch was
perfused via export catheter; the flow through catheter was approximately 40 ml/min. Since
the largest left main coronary artery branch was perfused with venous blood, tissue hypoxia
was achieved, and signs of CS were developed [87, 54]. CS in the studies was defined as a drop
in SBP to <100 mmHg and at least one of the following criteria: increase in blood lactate to
>2.0 mmol/L; decrease of SvO2 to <50 %; or fall in brain tissue oxygen saturation to <50 %.
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Figure 16: Initiation of regional cardiac hypoxia by perfusion with venous blood
If the above method did not cause signs of CS, the second balloon catheter was inserted into
the periphery of the second left main coronary artery branch.
4.1.5 The vital functions and hemodynamic parameters
A standard invasive method was used for arterial pressure measurement; for this purpose a
pigtail catheter and fluid-filled pressure transducers were applied (Truwave, Edwards Life-
sciences, LLC, USA). A pigtail catheter was inserted into the aortic arch. Pulmonary cardiac
output (pCO) was measured by a Swan–Ganz catheter; it was inserted via a femoral vein into
the pulmonary artery. Invasive central venous oxygen saturation, HR, pulse oximetry, inva-
sive blood pressures (aortic arch and jugular vein), capnometry, and electrocardiography were
continuously monitored (Monitor Life Scope TR, Nihon Kohden, Japan; and Vigilance II,
Edwards Lifesciences, USA). Near-infrared spectroscopy (INVOS Cerebral/Somatic Oxime-
ter, Somanetics, USA) was used for measurement of brain oxygenation levels [87, 88, 93].
Pressure-volume (PV) analysis was achieved by using a PV conductance catheter (Scisense
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7 Fr VSL Pigtail, Transonic, USA) which was connected to the PV unit (Sciense ADV 500,
Transonic, USA). The PV catheter was operated in admittance mode; it was introduced,
through the aortic valve, into the LV from the left carotid artery. Appropriate position of
the PV catheter was assessed radiographically by confirming optimal PV loop morphology.
The calibration of the volume was conducted against pulmonary thermodilution (Combo
CCO catheter, Edwards Lifesciences, USA) at baseline. Cardiac performance was continu-
ously monitored; PV data were recorded [87, 88, 93]. During the experiments values of SBP,
end-diastolic pressure (EDP), end-systolic volume (ESV), end-diastolic volume (EDV), and
value of stroke work (SW) were obtained (Table 2). The following parameters were calcu-
lated: SV = EDV−ESV; left ventricular ejection fraction (LVEF) LVEF = SV/EDV; left
ventricular cardiac output (LVCO) LVCO = SV ∗ HR; recirculation minute volume (RecV)
RecV = LVCO−pCO; recirculation fraction (RecF) RecF = RecV/LVCO.
4.1.6 Performing of the experiments conducted for the investigation of left ven-
tricular performance parameters
First of all the catheters were inserted and ECMO was established. Then the animals were
stabilized for 10 min. CS was induced and after achieving the signs of tissue hypoperfusion
the animals were stabilized for 10 min. After stabilization the EBF was gradually increased
by 1 L/min every 5 min to reach 5 L/min. When EBF 5 L/min was reached, EBF was
decreased gradually every 5 min by 1 L/min. When EBF reached 1 L/min, the animals were
stabilized for 10 min and the cycle of the measurement was repeated one more time [87]. The
steps of the experiment are shown in Figure 17.
4.1.7 Performing of the pilot experiment with the double lumen arterial cannula
First of all the catheters were inserted and ECMO was established. CS was induced and after
achieving the signs of tissue hypoperfusion the animal was stabilized for 10 min. Then the
arterial cannula, which was inserted through the femoral artery, was replaced by a DLAC
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Figure 17: The steps of the experiment in a porcine model of cardiogenic shock under veno-
arterial extracorporeal membrane oxygenation
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prototype. The tip of the reinfusion lumen of the prototype of the DLAC was placed in the
aorta. The tip of the drainage lumen of the prototype of the DLAC was inserted to LV,
as depicted in Figure 18. Then animal was stabilized for 10 min. After stabilization of the
Figure 18: The tip of the drainage lumen of the double lumen arterial cannula prototype in
the left ventricle
model of CS, the measurements of LV performance parameters were conducted. Primarily,
the drainage lumen of the DLAC was clamped, and the DLAC operated as a simple arterial
cannula; then, the clumped drainage lumen was unclamped and the cannula was used in full.
The cycle of the measurement was repeated six times.
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4.2 Drawing of the double lumen arterial cannula
The drafts of DLAC for ECMO was created in AutoCAD software. The drafts are presented
in Figures 19, 26, 27, 35 and in the Appendices C, D. AutoCAD is a computer-aided, pop-
ular engineering design software program for creating engineering drafting, developed and
marketed by Autodesk. It offers traditional 2D drawings as well as 3D drawing tools. The
AutoCAD software interface is shown in Figure 19.
Figure 19: AutoCAD software interface
4.3 Modeling and simulation
4.3.1 The Modelica modeling language
To create the model, the Modelica modeling language (Modelica Association) in the Dymola
(Dassault Systemes) modeling environment and components from Physiolibrary 2.3.1. were
used. The Modelica language is an object-oriented, hierarchical, equation-based and acausal
modeling language [109], in which models can be created and graphically represented from
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pre-prepared components or by connecting instances of classes from libraries [33, 70, 46]. The
Modelica interface is shown in Figure 20.
Figure 20: Modelica interface
Modelica is an acausal modeling language, which means that the equations that describe
the behavior of the compartment can be expressed declaratively and the Modelica tool de-
termines which of the variables are dependent and independent based on the context upon
a compilation [53]. In the created models, in Modelica, it is enough to set up the set of
parameters (if it needed), to start simulation [70]. Parameters in Modelica are the input
data, which are constant with respect to time [115]. In the result of the simulation, the user
can examine the change of variable values over time [70].
The main problem of medical research, articles, and experiments is using various units in
medicine, in pharmacology, in biology, and in non-physics disciplines. One of the advantages
of the Modelica environment is the support of non-SI units in the parameter dialog of each
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component. Values are represented by SI-units in the text code, but the Modelica environ-
ment supports non-SI units in the parameter dialog of each component [109]. Physiological
units are implemented as the displayUnits for each variable. Using displayUnits, the user
can establish and observe the “physiological” values [69].
Furthermore, Modelica is a multidomain programming language. The user has the op-
portunity to describe and connect model parts from varying domains in the model; such
as electrical, mechanical, thermodynamic, hydraulic, and biological domains. Modelica has
a general class concept that unifies classes, generics, and general subtyping into a single
language construct. This feature makes it easier to reuse components and aids in the devel-
opment of the models. Finally, Modelica has strong software for designing and connecting
components, meaning that this language is suitable for the architectural description of com-
plex physical and software systems [33].
4.3.2 Model description
The numerical model was employed to identify the association between the DLAC drainage
lumen size and the blood volume withdrawn from the LV during various EBF. After that, the
impact of ECMO venous cannula sizes on blood volume withdrawn from the LV during various
EBF was investigated. Consequently, the numerical model was employed to evaluate the effect
of the drainage lumen size of a DLAC and ECMO venous cannula size on LV unloading during
VA-ECMO, considering various EBF. Modelica code of the model is presented in Appendix E.
The required models of systemic circulation have been connected to models of the ECMO
system which were created to correspond with it and are necessary for research. The whole
created model consists of the following compartments: LV, right atrium, aorta, pump, tub-
ing set with an oxygenator, venous cannula, and lumens of the DLAC. The block diagram
representation of a system model is presented in Figure 21.
Each compartment is modeled using a mathematical relationship between blood volume
Vi(t), input flow rate Fiin(t) and output flow rate Fiout(t) relative to the i-th compartment
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Figure 21: The block diagram representation of a system model. LVPCC - left ventricular
pressures throughout cardiac cycle, A - aorta, OL – outflow lumen, ACP - arterial site of
the ECMO circuit, LV - left ventricle, RA - right atrium, IL - drainage lumen, VS - volume
sensor, VCP - venous site of the ECMO circuit, P - pump, OX - oxygenator, IC - inflow
cannula
given as [28]
dV i(t)
dt
= Fiin(j)− Fiout(j) (1)
with a flow rate Fij(t) between compartments i and j defined in general by [28]
Fij(t) =
Pi(t)−Pj(t)
Rij
j = i− 1 (2)
Analogous to Kirchhoff’s current law, which is applied in the electrical domain, the law sum-
to-zero is applied in the hydraulic domain to the flow variables. The sum of all mass flows
at any given point is zero [33]
Fin − Fout = 0 (3)
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Left ventricular pressure
The LV pressures were established according to a single cycle of cardiac activity time given
as in equation (4). The equation from Kulhanek et al. [53] for changing the flow, in the
heart chamber, was modified and adjusted for the expression of pressure in the LV [109].
The Figure 22 depicts LV pressures compartment in the Modelica language interface. The
parameters were set in accordance with the data obtained from experiments with a large
animal model of CS.
pressure =

diaPressure if tc < TD1
diaPressure+ sin
(
tc−TD1
TD2−TD1pi
)
(sysPressure− diaPressure) if tc < TD2
diaPressure else
(4)
Circuit
The circuit of the ECMO refers to the disposable tubing that forms the path that the blood
follows. The perfusionist is responsible for designing a circuit that meets the requirements;
that depends on many factors. Perfusion circuits vary from institution to institution, but
there are components common to all circuits [60]. The size of the ECMO circuit venous site
was set at 1/2 inch (1,27 cm) in the model. The size of the ECMO circuit arterial site was
set at 3/8 inch (0,95 cm). In the ECMO model, the standard arterial cannula was replaced
by a DLAC. The DLAC consists of two lumens, the shorter and the longer one. The shorter
lumen of the DLAC serves as a blood reinfusion lumen. The end of the shorter lumen is
positioned in the aorta. The cross-sectional area of the reinfusion lumen fits the size of
the 15 Fr peripheral cannula. The length of the reinfusion lumen was set to 60 cm. The
longer lumen of the DLAC, the end of which is introduced into the LV and serves as a blood
drainage lumen was, gradually increased from 5 Fr to 10 Fr. The length of the drainage
lumen was set to 120 cm. The size of the venous inflow cannula was chosen to be 21 Fr,
during the determination of the impact of drainage lumen size and extracorporeal blood flow
on DLAC unloading capacities; which is the same as in the experimental study with large
animal models with CS. The sizes of venous inflow cannulas were from 18 Fr to 29 Fr during
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(a)
(b)
Figure 22: Left ventricular pressures compartment in the Modelica language interface a) left
ventricular pressures compartment diagram b) left ventricular pressures compartment pro-
gramming code
56
the determination of the impact of venous cannula size on DLAC unloading capacities. The
length of the venous inflow cannula was set to 55 cm. The drainage lumen of the DLAC
and the venous inflow cannula were connected to the venous site of the ECMO circuit by a
Y shaped connector. The blood flows into the model compartments were described by the
Hagen–Poiseuille equation. The equation brings together all of the variables that determine
a flow
Q =
pi∆Pr4
8µL
(5)
The Hagen–Poiseuille equation states that the maximum flow is inversely proportional to
the lumen length and directly proportional to the fourth power of the radius for a circular
cross-section of the lumen [51]. The dynamic viscosity of blood 0.001 Pa·s was chosen [116].
The Figure 23 depicts the circuit compartment in the Modelica language interface.
Oxygenator
The oxygenator was modeled as a compartment with a pressure gradient [109].
∆P = Pin − Pout (6)
The value of pressure gradient per liter flow remains relatively constant during extracorporeal
circulation, and the only difference between different types of oxygenators is the absolute val-
ues obtained. Fisher et al. report the measurements in various manufacturers’ oxygenators.
In conclusion, there were no statistically relevant differences in the pressure gradient at any
timepoint during any bypass [30].
The Quadrox-i Adult oxygenator is a low-resistance, high-compliance oxygenator [119].
The parameters of adult hollow fiber membrane oxygenator Quadrox-i (Maquet Cardiopul-
monary AG) were used for the oxygenator submodel in the created model. The value for
mean pressure gradient per liter of Quadrox-i oxygenator is 10 mmHg [67]. The Figure 24
depicts the oxygenator compartment in the Modelica modeling language.
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(a)
(b)
Figure 23: The circuit compartment in the Modelica language interface a) circuit compart-
ment diagram b) circuit compartment programming code
Pump
The pump, in the ECMO system, supports or replaces the functions of the failing heart; it
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(a)
(b)
Figure 24: The oxygenator compartment in the Modelica language interface a) oxygenator
compartment diagram b) oxygenator compartment programming code
provides circulatory support [109]. The pump propels the blood throughout the body [60] and
the ECMO circuit. Required EBF can be easily set by the perfusionist and changed in case it
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is needed. The contemporary ECLS circuits include a magnetically levitated centrifugal pump
[95, 57]. The pump element was used from Modelica library for physiological calculations
- Physiolibrary 2.3.1 [110]. The flow rates of the model pump were setting at 1 L/min,
2 L/min, 3 L/min, 4 L/min, and 5 L/min for each tested size of DLAC drainage lumen, and
ECMO venous cannulas size. The Figure 25 depicts the pump compartment in the Modelica
language interface.
4.3.3 Parameters of the cardiovascular compartments
In the Modelica modeling language, the keyword “parameter” specifies that the quantity is
constant during a simulation run, but values can be changed between runs. A parameter is a
quantity that simplifies changing the behavior of a model by a user [26]. The parameters of
cardiovascular compartments, in the model, were obtained from a standard in vivo experiment
on a porcine model of CS. The parameter values of LV hemodynamic parameters were derived
from measurements described above. The selected LV performance parameters of a porcine
model of CS, which were used in the computer model, are presented in Table 1.
Table 1: The values of the model parameters
Extracorporeal blood flow 1 L/min 2 L/min 3 L/min 4 L/min 5 L/min
End-systolic volume [ml] 64 70 74 78 83
Systolic blood pressure [mmHg] 60 72 81 89 97
LV end-diastolic pressure [mmHg] 17.2 18.2 18.6 18.9 19
Heart rate [bpm] 94 89 84 80 77
4.3.4 The protocol of simulations
For the purpose of the simulation, the pump volume flow rate was gradually increased from
1 L/min to 5 L/min. For each value of the extracorporeal blood flow the value of SBP, LV
EDP, HR were changed in accordance with obtained data from an experiment on a porcine
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(a)
(b)
Figure 25: The pump compartment in the Modelica language interface a) pump compartment
diagram b) pump compartment programing code
model of CS (Table 1). The internal diameter of the drainage lumen of the DLAC was
gradually increased from 5 Fr to 10 Fr for each EBF value [109]. The internal diameter of
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the venous cannula was gradually increased from 18 Fr to 29 Fr for each drainage lumen of
DLAC sizes. The entire process was done for each unique combination of the pump flow,
drainage lumen size of the DLAC, peripheral venous cannula, and vital parameters which
were achieved from the porcine model of CS.
4.4 Statistical analysis
The data obtained from experiments with a porcine model of CS with a standard arterial
cannula during various EBF were analyzed by using GraphPad Prism 5.0 software (Graph-
Pad, USA). A repeated-measures one-way ANOVA with Tukey’s multiple comparison test,
or a Friedman test with Dunn’s multiple comparison test (for data sets without normal dis-
tribution) was used. The level for P value less than 0.05 was considered to be statistically
significant. To estimate the significant difference between selected hemodynamic parameters
in a porcine model of CS during EBF from 2 L/min to 5 L/min compared with value at EBF
1 L/min, the following clinical variables were tested: the SBP, EDP, ESV, EDV, SW, SV,
LVEF, CO, RecV, and RecF [87].
For the statistical analysis of the data, which were achieved during the pilot experi-
ment with the animal model of CS, the data were downloaded into R 3.5.3 for Windows
(The R Foundation, Vienna, Austria). R is a freely available language and environment for
statistical computation and graphics [118]. The box plots used to display a box that con-
tains the interquartile range with a line signifying the median, the whiskers (dashed line)
cover 1.5 times the interquartile range. The collected data that approximated a normal
distribution were reported as mean ± the standard error of the mean and were tested for
differences by the two-sample t-test. The collected data that did not approximate a normal
distribution were reported as a median ± standard error of the median and were analyzed
by the Wilcoxon rank-sum test (Mann-Whitney U test). Standard errors of the median were
computed by using a bootstrap approach. To estimate the significant difference between LV
performance during VA-ECMO with using a standard arterial cannula and LV performance
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during VA-ECMO with using DLAC, the following clinical variables were tested: arterial
diastolic pressure (ArtD), SBP, EDP, ESV, LVEF, EDV, SV, LV contractility (dP/dt). The
cut-off level for a P value of 0.05 or lower, which is the same as in the previous experiments,
was considered statistically significant.
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5 Results and discussion
The purpose of this chapter is to depict an experimental study with a porcine model of CS
under VA-ECMO and the effect of ECMO therapy on LV performance; to present an alterna-
tive method of LV unloading or LV overload reduction, which has the potential for reducing
the invasiveness of LV unloading during VA-ECMO therapy using a novel DLAC; further,
to describe DLAC parameters and features. Thereafter, to describe numerical modeling and
simulation to identify the association between both the drainage lumen size of the DLAC and
achieving LV decompression during ECMO therapy, and venous cannula size and achieving
LV decompression during ECMO therapy. The last part of the chapter depicts the pilot study
with a porcine model of CS under VA-ECMO, using DLAC instead of a standard arterial
cannula, to investigate the ability of DLAC to decompress LV during ECMO.
5.1 Left ventricular performance parameters in a porcine model
of CS under VA-ECMO
The aim of the experiment was to research and establish the impact of the VA-ECMO therapy
on the LV performance parameters in a porcine model of a CS. Collected data, during the
experiment, were then used for further modeling and simulation. The results of modeling
and simulation are described in the following paragraphs.
The measured data, during the experiment, and calculated data of vital functions and
hemodynamic parameters are listed in Table 2. The results of experimental studies indicated
that as a result of application of VA-ECMO, and with increasing EBF in the failing heart, SBP
is increased (P < 0.001) and HR is decreased (P < 0.001); these changes tended toward the
normal values. Furthermore, with increasing EBF and SBP, increasing in ESV (P < 0.001),
decreasing in SV (P = 0.045), decreasing in LVEF (P < 0.001) were observed; and as a conse-
quence, CO is decreased (P < 0.001). Although, EDV (P = 0.43) and EDP (P = 0.87) values
increased numerically with increasing EBF; nonetheless, these differences did not reach sta-
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Table 2: Collected data from experimental studies with the porcine model of cardiogenic
shock. EDP - end-diastolic pressure; EDV - end-diastolic volume; SBP - systolic blood
pressure; ESV - end-systolic volume; SW - stroke work; HR - heart rate; SV - SV; LVEF - left
ventricular ejection fraction; LVCO - left ventricular cardiac output. Results are expressed
as mean ± SEM
Extracorporeal blood flow 1 L/min 2 L/min 3 L/min 4 L/min 5 L/min P value
EDP [mmHg] 17.2±1.4 18.2±0.7 18.6±1.5 18.9±2.4 19.0±2.9 0.87
EDV [ml] 112±19 115±19 116±19 119±19 123±20 0.43
SBP [mmHg ] 60±7 72±7 81±6 89±7 97±8 < 0.001
ESV [ml] 64±11 70±11 74±11 78±12 83±14 < 0.001
SW [mmHg·ml] 2096±342 2510±335 2752±346 3031±404 2884±412 < 0.001
HR [bpm] 94±4 89±3 84±3 80±2 77±2 < 0.001
SV [ml] 48±9 45±9 42±9 41±9 40±8 0.045
LVEF [%] 43±3 39±2 36±3 34±3 32±3 < 0.001
LVCO [L/min] 4.31±0.40 3.90±0.47 3.49±0.51 3.21±0.40 2.99±0.38 < 0.001
tistical significance. However, EDV and EDP were notably affected not only by afterload but
also by preload. Also, the elevation of SW (P < 0.001) with increased EBF was observed [87].
An experimental study in a porcine model confirmed the undesirable negative effects of
VA-ECMO on LV performance parameters in flow dependent manner; with increasing EBF
the left heart performance deterioration was observed in the model of CS. The results of the
conducted study correspond with numerous other studies [40, 48, 16, 94, 47, 34, 106, 13].
As was mentioned in Chapter 2, numerous studies focused on the requirement to unload LV
during VA-ECMO; insufficient LV unloading can lead to LV distention and severe pulmonary
edema [8], which is often observed in patients with a severely depressed LV function on
high-flow VA-ECMO. Conducted experimental studies indicate deterioration of LV function
as a result of increasing EBF. The appropriate way to prevent complications such as LV
overload, caused by VA-ECMO, is applying low flow ECMO. However, a low flow ECMO is
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frequently not sufficient to achieve adequate end-organ tissue perfusion during extracorporeal
circulatory support. Despite the fact that a nonpulsatile centrifugal ECMO pump meets the
requirements of most institutions at the present time, nonpulsatile extracorporeal flow has
to maintain at least 20 % or 30 % higher flows than generally utilized for pulsatile flow, to
correct the abnormal physiology tends by itself [121]. The blood flow through the aorta of
a 70-kg man at rest is about 5 L/min [105], accordingly, 7 L/min nonpulsatile flow for a
70-kg person is recommended [121]. Thereby, mostly it is impossible to achieve adequate
tissue perfusion with low flow ECMO, and LV unloading is a necessary, required procedure
during VA-ECMO support. A number of methods have been suggested to deal with LV
unloading during VA-ECMO; however, each of the current methods require extra intervention
and increase invasiveness [110], which can lead to additional complications and can prolong
patient recovery time. An alternative method, of LV unloading, is the application of a novel
DLAC during VA-ECMO therapy. DLAC might provide a great opportunity to unload LV
and reinfuse the oxygenated blood to the circulation by one single cannula. Using DLAC
could be considered a less-invasive method than currently existing methods for decompressing
LV of the patient under VA-ECMO.
5.2 Double lumen arterial cannula for VA-ECMO
A known manner of performing VV-ECMO and hemodialysis utilizes is a single cannula in
which blood is both extracted and returned through the same cannula. Over the past years,
the double-lumen cannulas were widespread in the VV-ECMO therapy. This type of cannula
is less-invasive, reduces the circuit size and minimizes interaction between blood cells and
the circuit [51]. The DLAC is the novel variation of double lumen cannula. The DLAC is
a patented invention: Strunina, S.; Hozman, J.; Osˇtˇa´dal, P. A cannula containing a base
tube with two adjacent longitudinally leading lumens. Czech Technical University in Prague,
Faculty of Biomedical Engineering. Czech Republic. Patent. CZ 307196. 2018 - 01 - 31.
The patent document is presented in Appendix B. The object of the invention is to provide a
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DLAC for VA-ECMO which could be capable of achieving LV decompression and can reinfuse
the oxygenated blood with only one cannula, consequently only one puncture. Drafting of
DLAC for VA-ECMO in AutoCad environment is depicted in Figure 26.
Figure 26: Double lumen arterial cannula for veno-arterial extracorporeal membrane oxy-
genation in AutoCad environment
5.2.1 Summary of the invention
The novel DLAC for VA-ECMO (Figure 27) relates to surgical instruments. The DLAC is a
flexible one-piece cannula; the cannula is reinforced. This configuration decreases hemolysis
and prevents kinking or collapse of the cannula. A DLAC serves for reinfusion of oxygenated
blood and LV unloading during VA-ECMO. The present invention consists of a single arterial
cannula having two contiguous lumens, one is longer than the other. The shorter lumen, the
end of which is positioned in the aorta, serves as a blood reinfusion lumen. The longer
lumen, the end of which is introduced into the LV, serves as a blood drainage lumen [110].
With this arrangement, oxygenated blood is reinfused to the aorta and LV is unloaded by
one single cannula. The aforementioned cannula does not require further intervention to
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Figure 27: Drafting of the double lumen arterial cannula
achieve LV unloading during VA-ECMO as currently used methods for LV unloading during
VA-ECMO do. Under these circumstances, the risk of additional complications, caused by
further interventions, such as infection, bleeding and longer recovery time could be prevented.
The DLAC is inserted percutaneously over the guide wire, using the standard Seldinger
technique. It was shown that, using the Seldinger technique for the placement of femoral
venous cannulas in adult and pediatric patients results in fewer bleeding complications, less
costly cannulation procedures, and less complicated decannulations [96].
Seldinger’s technique sequence includes needle puncture, a guidewire through the needle,
removal of the needle; then inserting the vessel dilator over the guidewire into the vessel,
removal of the vessel dilator, threading of the cannula over a guidewire, and the removal
of the guidewire. A guidewire, which is used during Seldinger’s technique, is a flexible,
round-ended, metal leader [39]. An elongated lumen of DLAC, which is a drainage lumen,
is inserted to the LV through the femoral artery then through the aorta and aortic valve
(AV). The drainage lumen of DLAC has a pigtail tip. The pigtail tip serves to prevent the
wall of the heart chamber from being drawn to the catheter tip [110]. The drainage lumen
of the DLAC is connected by a Y connector to the venous site of the ECMO circuit; where
a centrifugal pump withdraws the blood from the right atrium and, in case of using DLAC,
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from the LV. Both drainage and reinfusion lumens of the DLAC have multiple side holes at
the tips. The side holes decrease mechanical stress on blood components [51], and increasing
the number of side holes generally reduces the mechanical stress on blood cells [90].
Park et al. reported that the angle of cannula side holes has a significant effect on the flow
pattern. In the Park et al. study, the side hole angles 0°, 15°, 30°, and 45° were investigated.
The angle represents the rotation of the hole from its original vertical position. A smoother
flow pattern occurs when the angle of cannula side holes increases, in addition an increase in
cannula side holes results in higher flow rate. Park indicated that a cannula with a 45° angle
of the side holes allows a higher flow rate and greater reduction of shear rate than cannulas
with 0°, 15°, 30° side hole angles [90]. Accordingly the angles of DLAC side holes are 45°
(Appendix D).
The catheters for the peripheral LV catheterization which are inserted in the femoral
artery must be approximately 120 cm long, in order to reach from the insertion point to LV.
Accordingly, the entire length of the cannula would be more than 120 cm (Appendix D).
The blood reinfusion lumen, which returns the oxygenated blood to the circulation, is about
60 cm length (Appendix D). The length of the drainage lumen, which withdraws the blood
from LV for unloading of LV during VA-ECMO, is about 120 cm (Appendix D).
The inserted length of the cannula can be changed according to requirements. Therefore,
the DLAC is suitable for patients with different anatomical features and parameters.
The radiopaque markers, located in the DLAC distal end, are used to denote the location
of the distal end.
5.2.2 Description of the preferred embodiment
The DLAC in accordance with the present invention is designed for LV unloading and rein-
fusion of the oxygenated blood to the patient‘s circulatory system during VA-ECMO. Ap-
pendix C presents the drawings for the description of the preferred embodiment.
Referring to Figure 1 in Appendix C it can be seen that the present invention consists
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of a single arterial cannula (1), comprising an elongated tubing (2), has two longitudinally
spaced lumens (3 and 4). The lumens are separated.
Figure 1 in Appendix C is a side cross-sectional view of a cannula in accordance with the
present invention.
The drainage lumen (4) of the DLAC, which extends from the proximal end of the cannula
to the distal end (6) of the cannula, is terminated by one or more side holes or perforations (7)
at the distal end of the lumen. The drainage lumen (4) size is about 10 Fr (3.3 mm) in
diameter. Figure 3 in Appendix C is a transverse cross-sectional view of a lumen (4) in
accordance with the present invention, shown along line B-B.
The reinfusion lumen (3) of the DLAC, which leads from the proximal end (18) of the
cannula to the position of the reinfusion lumen end (8), is terminated by one or more side
holes or perforations (9).
Figure 2 in Appendix C shows a cross-sectional view of a cannula in accordance with the
present invention, shown along line A-A.
Side holes or perforations (7) at the distal end of the drainage lumen extends beyond the
side holes or perforations (9) at the end of the reinfusion lumen by 60 centimeters. The distal
end of the drainage lumen (4) is inserted into the LV. The end of the reinfusion lumen (3)
locates in the aorta.
The inserted length of the cannula, the separation “12” would be approximately 120 cm.
The separation “13” on Figure 1 in Appendix C would be approximately 60 cm. The non-
inserted ends of the lumens are connected to the ECMO circuit. This connection can be
accomplished by separating the lumens 3, 4 into two noncontiguous tubes (10, 11) of circular
cross-section. The length of the connecting tubes 10, 11, the separations “14, 15” would be
approximately 7 cm.
The distal end of the drainage lumen (2) has a pigtail tip, which can be straightened by
the passage of a guidewire to allow the pigtail to be passed through the aortic valve into the
LV. The guide wire is then withdrawn, leaving the pigtail catheter in the LV, so that the
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pigtail resumes its shape in the LV.
The proximal ends of lumens 16 and 17 are adapted to attach to the ECMO circuit by
connecting with standard 3/8 inch (9.52 mm) connectors.
A suitable material for the cannula (1) is Teflon (polytetrafluoroethylene) or polyurethane.
Manufacturing drawings of DLAC are presented in Appendix D.
5.3 Double lumen arterial cannula capacities for left ventricular
overload reduction during VA-ECMO therapy
The LV decompression is associated with a significant improvement of the LV function during
the VA-ECMO therapy [25]. As was mentioned before, an alternative method to prevent LV
overload during VA-ECMO is the application of the novel DLAC. As outlined earlier, DLAC
is a peripheral, flexible, dual lumen cannula. The first lumen is longer and the second lumen
is shorter. The longer lumen serves for LV decompression; the tip of the longer lumen
introduced into the LV through the aortic valve and serves as a blood drainage lumen. The
drainage lumen (the longer lumen) of the DLAC is connected to the venous side of the ECMO
circuit by a Y-shaped connector and the blood is withdrawn by the centrifugal pump from the
LV (Figure 28). The shorter lumen of DLAC, the outflow lumen, serves to reinfuse into the
aorta blood that has been oxygenated in the oxygenator. Thereby, oxygenated blood returns
to the aorta and LV is unloaded by one single cannula which requires only one puncture
[110]. The effect on LV decompression of the diameter of the drainage lumen of the DLAC
and the EBF value were investigated using modeling and simulation. The main objective of
the simulation study was to assess the unloading capacities of various diameters of the DLAC
drainage lumen during various EBF values, and various venous cannula sizes.
The Modelica modelling language was employed 1) to identify the associations between
DLAC drainage lumen diameter and volume value withdrawn from the LV during ECMO;
2) to identify the associations between EBF value and volume value withdrawn from the LV
by the drainage lumen of DLAC; 3) to identify the associations between venous cannula size
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Figure 28: Left ventricular unloading by the double lumen arterial cannula during veno-
arterial extracorporeal membrane oxygenation
and volume value withdrawn from the LV by the drainage lumen of DLAC. Consequently,
to evaluate the effect of the drainage lumen diameter, EBF, and venous cannula size on the
LV unloading. The data of hemodynamic and cardiac performance parameters, which were
obtained from the experimental studies with the porcine model of CS on VA-ECMO, were
used for creating the model.
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5.3.1 Impact of drainage lumen size and extracorporeal blood flow on DLAC
unloading capacities
The outcomes of the simulation on the created model have estimated that 5 Fr drainage
lumen of DLAC withdraws from 0.23 ml to 0.41 ml for the cardiac cycle during EBF from
1 L/min to 5 L/min; 6 Fr drainage lumen of DLAC withdraws from 0.48 ml to 0.85 ml for
the cardiac cycle during EBF from 1 L/min to 5 L/min; 7 Fr drainage lumen withdraws from
0.88 ml to 1.57 ml for the cardiac cycle during EBF from 1 L/min to 5 L/min; 8 Fr drainage
lumen withdraws from 1.5 ml to 2.69 ml for the cardiac cycle during EBF from 1 L/min to
5 L/min; 9 Fr drainage lumen withdraws from 2.38 ml to 4.26 ml for the cardiac cycle during
EBF from 1 L/min to 5 L/min; 10 Fr drainage lumen withdraws from 3.59 ml to 6.42 ml for
the cardiac cycle during EBF from 1 L/min to 5 L/min. Table 3 presents the results of the
simulations.
The flow rate value through the drainage lumen throughout the cardiac cycles is not
constant; the flow rate is varied throughout the cardiac cycles. Figure 29 depicts flow rate
profiles of the blood throughout the cardiac cycles, which is withdrawn from LV by drainage
lumen of the DLAC, according to drainage lumen size. The main point of this paragraph
is the determination of the withdrawal volume amount from LV by drainage lumen of the
DLAC for the one cardiac cycle. Figure 29 depicts the variation with time of the volume
value withdrawn from LV by drainage lumen of the DLAC according to drainage lumen size;
the red circles on Figure 29 depict volume values withdrawn from LV for one cardiac cycle.
Figure 30 depicts the simulation results of the variation with time of withdrawal volume
values from left ventricle by various sizes of DLAC drainage lumen in the Modelica interface
for one cardiac cycle. Figure 31 depicts withdrawal volume values for a cardiac cycle according
to the drainage lumen size. The relationship between the withdrawal volume value for a
cardiac cycle and the EBF is shown in Figure 32.
Computer simulation/mathematical modeling can provide relevant mechanistic insights
and enhance our pathophysiological understanding of complex ECMO configurations aims
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Figure 29: Flow rate profiles throughout the cardiac cycle and the variation with time of
the volume value withdrawn from left ventricle by the drainage lumen of the double lumen
arterial cannula, EBF 4 L/min. The red circles depict volume values withdrawn from left
ventricle for one cardiac cycle
at LV unloading. The conducted study indicates that the size of the drainage lumen is a
more influential factor than EBF for LV decompression by DLAC during VA-ECMO therapy.
Increasing of EBF value, during the application of a certain size of the drainage lumen, only
slightly decreased cardiac loading.
During the simulation, a reverse flow, throughout the drainage lumen was observed (Fig-
ure 33); this can be caused by interactions of the pressures in the Y connector, and/or
the pressure changes in LV throughout the cardiac cycle. Nevertheless, to establish the cause
it is necessary to conduct additional investigations.
From the experiment with large animal models of CS it was determined, that with in-
creases of EBF the LV ESV increased from 64 ml (baseline) to 70 ml, 74 ml, 78 ml and
83 ml, respectively (EBF 1–5 L/min) (Table 2); thereby, ESV is increased by 6 ml, 10 ml,
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(a) EBF 1 L/min (b) EBF 2 L/min
(c) EBF 3 L/min (d) EBF 4 L/min
(e) EBF 5 L/min
Figure 30: Withdrawal volume values from left ventricle by various sizes of double lumen
arterial cannula drainage lumen in the Modelica interface. The values can be found in Table 3.
EBF - extracorporeal blood flow. a) EBF 1 L/min; b) EBF 2 L/min; c) EBF 3 L/min; d)
EBF 4 L/min; e) EBF 5 L/min
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Figure 31: Withdrawal volume values for a cardiac cycle according to the size of drainage
lumen of the double lumen arterial cannula. The values can be found in Table 3
14 ml, 19 ml with increasing EBF from 1 L/min to 2 L/min, from 2 L/min to 3 L/min, from
3 L/min to 4 L/min, from 4 L/min to 5 L/min, respectively. Table 3 presents the simulation
results of volume values withdrawn from LV for one cardiac cycle. Drainage lumen size range
from 5 Fr to 10 Fr, EBF value varies from 1 L/min to 5 L/min. As a result of withdrawal the
stagnated blood from LV by the drainage lumen of DLAC, 5 Fr drainage lumen unload LV
by 5 %, 3.3 %, 2.7 %, 2 %, during EBF 2 L/min, 3 L/min, 4 L/min, 5 L/min respectively;
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Figure 32: The effect of veno-arterial extracorporeal membrane oxygenation blood flow on
withdrawal volume value by the drainage lumen of the double lumen arterial cannula for the
cardiac cycle. The values can be found in Table 3
6 Fr drainage lumen withdrew 10%, 7%, 5 %, 4 % of stagnated blood during EBF 2 L/min,
3 L/min, 4 L/min, 5 L/min respectively; 7 Fr drainage lumen withdrew from 18 % to 12 %,
10 %, 8 % during EBF from 1 L/min to 5 L/min; 8 Fr drainage lumen withdrew 31 %, 21 %,
17 %, 14 % of stagnated blood during EBF 2 L/min, 3 L/min, 4 L/min, 5 L/min respectively;
9 Fr drainage lumen withdrew from 48 % to 34 %, 27 %, 22 % during EBF from 1 L/min to
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Table 3: Simulated results of blood volume drained from left ventricle for single cardiac cycle
by the drainage lumen of the double lumen arterial cannula during veno-arterial extracorpo-
real membrane oxygenation
Drainage lumen size [Fr]
Extracorporeal blood flow
1 L/min 2 L/min 3 L/min 4 L/min 5 L/min
Withdrawn blood volume during single cardiac cycle [ml]
5 0.232 0.282 0.328 0.373 0.414
6 0.476 0.580 0.675 0.768 0.852
7 0.876 1.067 1.241 1.411 1.565
8 1.504 1.833 2.131 2.423 2.688
9 2.384 2.905 3.377 3.840 4.260
10 3.591 4.375 5.087 5.784 6.417
5 L/min respectively; 10 Fr drainage lumen unloaded LV by 73 %, 51 %, 41 %, 34 %, during
EBF 2 L/min, 3 L/min, 4 L/min, 5 L/min respectively (Figure 34) compared with baseline.
The percentages of LV unloading were calculated using the results of simulations.
It is absolutely understandable that the larger the size of the DLAC drainage lumen
that is be used, the greater the degree of unloading that will be achieved. However, human
physiological features must be taken into account; the DLAC cannot exceed a limited size
which is defined by the physiological properties of human blood vessels. In addition, DLAC
must have the appropriate size of reinfusion lumen in order to provide the necessary flow.
To ensure sufficient tissue oxygenation, an appropriate flow through the reinfusion lumen is
required. The cross-sectional area of the DLAC reinfusion lumen approximately corresponds
to the 15 Fr cannula; DLAC cross-sectional area equals 20.67 mm2 (Figure 35).
An increasing of one lumen increased the whole size of the cannula; the common size of
the femoral artery in an adult is 6.6 mm in diameter (3.9 – 8.9 mm) [108], and the size of the
DLAC cannot exceed these dimensions. DLAC with a 10 Fr drainage lumen has diameter
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Figure 33: Reverse flow throughout the drainage lumen during left ventricular unloading by
double lumen arterial cannula, extracorporeal blood flow 4 L/min
7 mm; this size is appropriate for insertion to the common femoral artery of an adult person.
In addition, the smaller the size of the cannula, the lower the probability of side effects such
as bleeding, the risk of vascular damage, ischemia, and obstruction of arteries.
The results of conducted simulations have estimated that the DLAC for VA-ECMO with
a 10 Fr drainage lumen presents a promising solution to achieve reduction of the LV loading
during VA-ECMO, and it could be considered a less invasive than by the methods proposed
to date. The smaller diameter of drainage lumen could be used; nevertheless, a lesser degree
of LV unloading could be achieved.
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Figure 34: The percentage of left ventricular unloading during veno-arterial extracorporeal
membrane oxygenation by double lumen arterial cannula
5.3.2 Impact of venous cannula size on DLAC unloading capacities
The results of the simulation indicate that with decreasing of the size of the venous cannula
from 29 Fr to 18 Fr, an increase in blood withdrawal by the DLAC drainage lumen from
LV was observed from 0.258 ml to 0.31 ml during EBF 2 L/min, from 0.29 ml to 0.373 ml
during EBF 3 L/min, from 0.32 ml to 0.436 ml during EBF 4 L/min, from 0.345 ml to
0.496 ml, during EBF 5 L/min throughout 5 Fr drainage lumen; from 0.532 ml to 0.637 ml,
from 0.597 ml to 0.766 ml, from 0.659 ml to 0.895 ml, from 0.71 ml to 1.017 ml during
EBF 2 L/min, 3 L/min, 4L/min, 5L/min respectively throughout 6 Fr drainage lumen; from
0.98 ml to 1.168 ml, from 1.1 ml to 1.404 ml, from 1.213 ml to 1.641 ml, from 1.307 ml
to 1.866 ml, during EBF 2 L/min, 3 L/min, 4L/min, 5L/min respectively throughout 7 Fr
drainage lumen; from 1.688 ml to 2 ml, from 1.895 ml to 2.404 ml, from 2.089 ml to 2.81 ml,
from 2.251 ml to 3.194 ml, during EBF 2 L/min, 3 L/min, 4 L/min, 5 L/min respectively
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Figure 35: The cross-sectional area of the double lumen arterial cannula reinfusion lumen
throughout 8 Fr drainage lumen; from 2.686 ml to 3.155 ml, from 3.016 ml to 3.791 ml, from
3.325 ml to 4.432 ml, from 3.583 ml to 5.038 ml, during EBF 2 L/min, 3 L/min, 4 L/min,
5 L/min respectively throughout 9 Fr drainage lumen; from 4.069 ml to 4.722 ml, from
4.569 ml to 5.674 ml, from 5.036 ml to 6.632 ml, from 5.427 ml to 7.539 ml during EBF
2 L/min, 3 L/min, 4 L/min, 5 L/min respectively throughout 10 Fr drainage lumen. The
results of simulation with venous cannula sizes from 18 Fr to 29 Fr and for DLAC drainage
lumen sizes from 5 Fr to 9 Fr are presented in Appendix F.
The Figure 36 depicts withdrawal volume values for a cardiac cycle by 10 Fr drainage
lumen of DLAC, with venous cannulas from 18 Fr to 29 Fr, during various EBF in the
Modelica interface. The Figure 37 presents withdrawal volume values by 10 Fr drainage
lumen, with venous cannula sizes from 18 Fr to 29 Fr for one cardiac cycle; EBF value varies
from 1 L/min to 5 L/min.
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(a) (b)
(c) (d)
(e)
Figure 36: Withdrawal volume values for a cardiac cycle by 10 Fr drainage lumen, with
venous cannulas from 18 Fr to 29 Fr in the Modelica interface. EBF - extracorporeal blood
flow. a) EBF 1 L/min; b) EBF 2 L/min; c) EBF 3 L/min; d) EBF 4 L/min; e) EBF 5 L/min
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The Table 4 presents the simulation results of volume values withdrawn from LV for one
cardiac cycle by 10 Fr drainage lumen of DLAC. EBF value varies from 1 L/min to 5 L/min.
The venous cannula size varies from 18 Fr to 29 Fr.
Figure 37: Blood volume withdrawn from left ventricle by 10 Fr drainage lumen of the double
lumen arterial cannula for a cardiac cycle with venous cannula sizes from 18 Fr to 29 Fr. The
values can be found in Table 4
As was mentioned above, VA-ECMO, and increasing EBF causes increasing ESV, witch
means stagnation of the blood in the LV. The drainage lumen of DLAC withdraws the stag-
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nated blood from LV, and as a result LV overload might be reduced. The percentages of
LV unloading were calculated using the results of simulations on the created model. With a
decrease of ECMO venous cannula size, LV unloading seems to have been increased in com-
parison with baseline. The data for the unloading percentages are presented in Appendix H.
Table 4: Simulated results of blood volume drained from left ventricle by 10 Fr drainage
lumen of double lumen arterial cannula, with venous cannula sizes from 18 Fr to 29 Fr
ECMO venous
cannula size [Fr]
Extracorporeal blood flow
1 L/min 2 L/min 3 L/min 4 L/min 5 L/min
Withdrawn blood volume during single cardiac cycle [ml]
18 3.726 4.722 5.674 6.632 7.539
19 3.670 4.578 5.431 6.281 7.074
20 3.625 4.463 5.236 5.999 6.701
21 3.591 4.375 5.087 5.784 6.417
22 3.563 4.305 4.968 5.613 6.190
23 3.541 4.247 4.870 5.471 6.003
24 3.523 4.202 4.794 5.360 5.856
25 3.509 4.165 4.731 5.270 5.737
26 3.497 4.133 4.678 5.193 5.635
27 3.487 4.108 4.635 5.132 5.554
28 3.479 4.087 4.600 5.080 5.486
29 3.472 4.069 4.569 5.036 5.427
Figure 38 depicts the percentage of LV unloading during VA-ECMO by 10 Fr drainage
lumen of DLAC with ECMO venous cannula from 18 Fr to 21 Fr, during various EBF.
As was mentioned in the previous paragraph, the larger the size of the DLAC drainage
lumen that is used, the greater the degree of unloading that will be achieved. Nevertheless,
the size of the DLAC drainage lumen must not exceed 10 Fr on account of human physiological
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Figure 38: Percentage of left ventricular unloading during veno-arterial extracorporeal mem-
brane oxygenation by 10 Fr double lumen arterial cannula drainage lumen with venous can-
nula sizes from 18 Fr to 21 Fr
features. This paragraph describes the circumstances of a possible increase in the degree of
LV unloading by increasing flow through the drainage lumen of DLAC, without an increase
in DLAC size. In this paragraph, the comparison of the degree of LV unloading with the
application of venous cannulas from 18 Fr to 29 Fr is done. The reason for choosing venous
cannula sizes from 18 Fr to 29 Fr is that standard ECMO venous cannula sizes for adults
are from 18 Fr to 29 Fr. The venous cannula 21 Fr was used in the study mentioned in the
paragraph above.
The simulation study indicates, that with decreasing venous cannula size, the percentage
of LV loading during VA-ECMO decreases. The flow through the drainage lumen of DLAC
is increased with decreasing venous cannula size; therefore, achieving a better result of LV
unloading during VA-ECMO. Consequently, the smaller the venous cannula that is used,
the higher the value of LV unloading that is achieved by the drainage lumen of DLAC; in
addition, as was mentioned before, the lower the size of the cannula, the lower the probability
of the occurrence of complications associated with the introduction of peripheral cannulas.
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5.4 The pilot study with double lumen arterial cannula in porcine
model of cardiogenic shock
The aim of the experiment was to research and establish the impact of DLAC aplication
during the VA-ECMO therapy on the LV performance parameters in a porcine model of a
CS. The animal underwent VA-ECMO implantation under general anesthesia and artificial
ventilation. After inducing of acute CS with signs of tissue hypoxia, hemodynamic and car-
diac performance parameters were measured with a clamped drainage lumen of DLAC and
consistently unclamped drainage lumen of DLAC. DLAC with a clamped drainage lumen
acts as a standard peripheral cannula; therefore, the collected data during clamped drainage
lumen were presented as hemodynamic and cardiac performance parameters using standard
peripheral cannula. For the measurement of hemodynamic and cardiac performance param-
eters a pressure-volume loop catheter (placed in the LV), arterial and venous catheters, and
pulmonary artery catheter were used.
With the application of DLAC instead of standard arterial cannula during VA-ECMO,
an decreasing in ArtD was observed from 99.0±5.0 mmHg to 66.67±6.6 mmHg (P<0.05)
(Figure 39a); SBP decreased from 127.2±7.4 mmHg to 97.17±8.4 mmHg (P<0.05) (Fig-
ure 39b); EDP decreased from 21.83±0.9 mmHg to 16±0.51 mmHg (P<0.05) (Figure 39c);
ESV decreased from 127.8±2.5 ml to 113.8±3.6 ml (P<0.05) (Figure 39d), LVEF (increased
25.5±1.4 % to 32.67±2.2 %; P<0.05) (Figure 39e). There was no significant difference in
EDV (decreased 171.5±1.9 ml to 168±3 ml; P=0.2) (Table 5), SV (increased from 43.67±2.6
ml to 54.83±4.33 ml; P=0.051) (Table 5), and dP/dt (increased from 721.2±85.2 mmHg/s
to 907.8±92.5 mmHg/s; P=0.16) (Table 5).
Table 5 presents selected hemodynamic parameters of the animal model of CS during
VA-ECMO with the use of standard arterial cannula and using DLAC during VA-ECMO.
As a consequence of applying VA-ECMO, as a side effect, the overload and impairment of
LV function might occur. The findings from this study provide evidence that the use of DLAC
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(a) (b)
(c) (d)
(e)
Figure 39: The effect of using double lumen arterial cannula during veno-arterial extracor-
poreal membrane oxygenation on left ventricular functional parameters in a porcine model
of cardiogenic shock. ArtD - arterial diastolic pressure, SBP - systolic blood pressure, EDP -
end-diastolic pressure, ESV - end-systolic volume, LVEF - ejection fraction
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Table 5: The selected hemodynamic parameters in a porcine model of cardiogenic shock
during veno-arterial extracorporeal membrane oxygenation with using standard arterial can-
nula and with the use of DLAC during VA-ECMO. The values are reported as mean ± the
standard error of the mean
Parameters
Standard arterial
cannula
DLAC P value
Left ventricular end-diastolic volume [ml] 171.5±1.9 168±3 0.13
Left ventricular stroke volume [ml] 43.67±2.6 54.83±4.33 0.051
Left ventricular contractility [mmHg/s] 721.2±85.2 907.8±92.5 0.16
instead of a standard peripheral cannula during VA-ECMO had a beneficial effect on selected
LV parameters. The application of DLAC in medical practice can make the elimiantion of
LV loading possible, or at least to achieve a LV loading reduction to prevent LV overload
during VA-ECMO therapy. Using DLAC might be an alternative method, which could be
considered less-invasive than currently used methods for LV unloading during VA-ECMO.
The analysis of archived data indicate that ArtS, ArtD, SBP, EDP, ESV were significantly
lover (P<0.05) and LVEF was significantly greater (P<0.05) during VA-ECMO with DLAC
than that during VA-ECMO with a standard arterial cannula.
One of the most important aspects of VA-ECMO is the impairment of performance of
the LV [73] during ECMO therapy. Numerous studies have indicated that direct LV decom-
pression by placing a vent into the LV eliminate LV function deterioration, organ function
deterioration, and improve survival outcomes [27, 29, 120]. According to the obtained infor-
mation, Impella is considered the most powerful tool for LV decompression during VA-ECMO
[89, 8]; nonetheless the application of Impella may lead to significant hemolysis [12]. Bar-
bone et al. [13], and Hong et al. [42] report trans-aortic catheter venting of LV during
ECMO (the vent was connected to the venous site of the ECMO circuit) which leads to
acceptable LV unloading. These studies correspond with the conducted study with DLAC
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in a porcine model of CS. In addition, using DLAC do not require the additional interven-
tions and could be considered a less-invasive method of LV unloading, than other methods
proposed to this date.
The limitations of the experiment related to small numbers. To better understand the
impact of DLAC on LV performance more accurate population-based data sets that con-
tain accurate clinical information are needed. A higher powered study is necessary to verify
and confirm DLAC effects on LV performance. In future studies, it will be important to
investigate the impact of using DLAC on outcomes such as time to recovery, medical com-
plications, and cost.
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6 Summary and future perspectives
The outcomes of VA-ECMO is improved with the appearance of newer technologies, and the
role of ECMO in the treatment of patients with severe CS and CA refractory to conventional
medical therapy and standard resuscitation methods has continued to evolve.
Biomedical engineering is a broad field that covers a wide range of activities.
“Bioengineering is usually defined as a basic research-oriented activity closely related to
biotechnology and genetic engineering . . . on the other hand, apply electrical, mechanical,
chemical, optical, and other engineering principles to understand, modify, or control biologic
(i.e., human and animal) systems, as well as design and manufacture products that can
monitor physiologic functions and assist in the diagnosis and treatment of patients” [19].
Among other things, biomedical engineering involves advising manufacturers of medical
devices on promising improvements based on clinical experience; the application and imple-
mentation of medical technologies to optimize the delivery of medical care. These aspects of
biomedical engineering are realized in this thesis. The thesis presents, an alternative method
of LV unloading, which has the potential for reducing the invasiveness of LV unloading dur-
ing VA-ECMO therapy. The incorporation of the developed method of LV unloading in
medical practice is going to improve the emptying of the LV during ECMO, and to prevent
LV overload during VA-ECMO therapy. It is intended that the findings will contribute to
the mitigation of such ECMO complications as LV overload; furthermore, elimination of the
complications, of currently existing methods for LV decompression, such as an additional
source of bleeding, infection, and longer recovery time of ECMO treated patients.
In the thesis were described in detail, hemodynamic and cardiac performance parame-
ters in ECMO treated individuals with CA and CS. Then currently existing methods were
described for LV unloading in VA-ECMO treated individuals. Furthermore, the impact of
ECMO therapy on LV performance in large animal models of CS was investigated. The exper-
imental data demonstrated unsatisfactory LV unloading during high-flow VA-ECMO; it may
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cause impairment of LV performance in a flow-dependent manner in CS. ECMO can induce
LV dilatation, pulmonary edema, and deterioration of LV function. The adequate drainage
of LV during VA-ECMO is a crucial factor in the patient outcome. The existing methods
for LV unloading require additional interventions [110], which increase the risk of compli-
cations such as infection, bleeding and longer recovery times. In the thesis an alternative
method, which has the potential for reducing the invasiveness of LV unloading during VA-
ECMO therapy is proposed. The application of the DLAC might be considered less-invasive
approach than currently existing methods for reducing LV overload during VA-ECMO; the
DLAC might unload the LV and infused oxygenated blood to the circulation while requiring
only one puncture. The DLAC is a patented invention; it is a one piece reinforced cannula
with side holes at the tips of the lumens. This configuration avoids kinking or collapse of the
cannula, decreases hemolysis, and allows a higher flow rate and greater reduction of shear
rate. Based on acquired data from large animal models of CS, the model was created, and the
value of LV decompression by using the proposed alternative method of LV unloading was
established. The sufficient size of drainage lumen of DLAC was identified. The simulation
study demonstrates that the value of withdrawal volume by the drainage lumen, connected
to the venous site of the ECMO circuit, depends mainly on the size of the drainage lumen.
The study indicates that DLAC with 10 Fr drainage lumen achieves the purpose of reducing
LV loading, and meets the typical physiological dimensions of the femoral artery of an adult.
Based on the modeling and simulation, circumstances under which to increase the value of LV
decompression by using DLAC without increasing DLAC size were identified. The method
of increasing flow through the drainage lumen of DLAC, and thus to provide a greater degree
of LV unloading is decreasing ECMO venous cannula. The simulated study indicates that
the optimal conditions for achieving the best result of LV unloading by DLAC during ECMO
are as large as possible drainage lumen and as small as possible ECMO venous cannula.
The pilot study was conducted to investigate the impact of the DLAC during VA-ECMO
on LV performance in large animal model of CS. The pilot experiment indicated significant
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improvement in selected hemodynamic parameters and LV performance.
DLAC presents a promising solution and has the potential for reducing the invasiveness
of LV unloading during VA-ECMO therapy. The application of the DLAC might be a novel
method of LV overload reduction, which gives good grounds for expecting to mitigate negative
sequelae of VA-ECMO; it is intended that the implication of DLAC in medical practice will
contribute to the mitigation of ECMO complications such as LV overload.
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Symbols and abbreviations
∆P Pressure reduction
µ Dynamic viscosity
PCO Pulmonary cardiac output
LVCO Left ventricular cardiac output
ArtD Arterial diastolic blood pressure
AV Aortic valve
BBAS Blade and balloon atrial septostomy
BV LD Bivalirudin
CRP Cardiopulmonary resuscitation
CS Cardiogenic shock
diaPressure Diastolic blood pressure
DLAC Double lumen arterial cannula
dP/dt Left ventricular contractility
EBF Extracorporeal blood flow
ECLS Extracorporeal life support
ECMO Extracorporeal membrane oxygenation support
EDP Left ventricular end-diastolic pressure
110
EDV Left ventricular end-diastolic volume
ESV Left ventricular end-systolic volume
Fiin Input flow rate
Fiout Output flow rate
Fij Flow rate between compartments i and j
Fin Input flow
Fout Output flow
HR Heart rate
IABP Intra-Aortic Balloon Pump
IABP − SHOCK Intra-Aortic Balloon Pump in cardiogenic shock
L Length of pipe
LCS Life circulatory support
LV Left ventricle
LV EF Left ventricular ejection fraction
Pi A pressure of compartment i
Pj A pressure of compartment j
Pin Input pressure
Pout Output pressure
PAWP Pulmonary artery wedge pressure
PPAam Plasma polymerized allylamine
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PV Pressure-volume
Q Volumetric flow rate
r Pipe radius
Rij A resistance between compartments i and j
RecF Recirculation fraction
RecV Recirculation minute volume
ROSC Return of spontaneous circulation
SBP Left ventricular systolic blood pressure
SS Stainless steel
SV Left ventricular stroke volume
SvO2 Venous oxygen saturation
sysPressure Systolic blood pressure
tc Relative time in cardiac cycle
TD1 Relative time of start of systole
TD2 Relative time of end of systole
TLP Tethered–Liquid Perfluorocarbon
Vi Blood volume
V A− ECMO Veno-arterial extracorporeal membrane oxygenation
V V − ECMO Veno-venous extracorporeal membrane oxygenation
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Appendix D: Manufacturing drawings of double lumen
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Appendix E: Modelica code of the model
The model code is on the CD attached to the doctoral thesis.
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Appendix F: Simulation results of withdrawal blood value
through DLAC drainage lumen, for single cardiac cycle,
with applying from 18 Fr to 29 Fr venous cannula sizes
Table 6: The results of simulation with applying from 18 Fr to 29 Fr venous cannula sizes
for 5 Fr DLAC drainage lumen
ECMO venous
cannula size [Fr]
Extracorporeal blood flow
1 L/min 2 L/min 3 L/min 4 L/min 5 L/min
Withdrawn blood volume during single cardiac cycle [ml]
18 0.245 0.310 0.373 0.436 0.496
19 0.239 0.299 0.354 0.410 0.462
20 0.235 0.289 0.340 0.389 0.435
21 0.232 0.282 0.328 0.373 0.414
22 0.229 0.277 0.320 0.361 0.398
23 0.227 0.272 0.312 0.351 0.385
24 0.225 0.269 0.307 0.343 0.375
25 0.224 0.266 0.302 0.337 0.366
26 0.223 0.263 0.298 0.331 0.359
27 0.222 0.261 0.295 0.327 0.354
28 0.221 0.260 0.293 0.323 0.349
29 0.220 0.258 0.290 0.320 0.345
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Table 7: The results of simulation with applying from 18 Fr to 29 Fr venous cannula sizes
for 6 Fr double lumen arterial cannula drainage lumen
ECMO venous
cannula size [Fr]
Extracorporeal blood flow
1 L/min 2 L/min 3 L/min 4 L/min 5 L/min
Withdrawn blood volume during single cardiac cycle [ml]
18 0.503 0.637 0.766 0.895 1.017
19 0.492 0.613 0.728 0.842 0.948
20 0.483 0.595 0.698 0.799 0.893
21 0.476 0.580 0.675 0.768 0.852
22 0.471 0.569 0.657 0.742 0.819
23 0.467 0.560 0.642 0.722 0.792
24 0.463 0.553 0.631 0.705 0.771
25 0.461 0.547 0.621 0.692 0.754
26 0.458 0.542 0.613 0.681 0.739
27 0.457 0.538 0.607 0.672 0.728
28 0.455 0.535 0.602 0.665 0.718
29 0.454 0.532 0.597 0.659 0.710
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Table 8: The results of simulation with applying from 18 Fr to 29 Fr venous cannula sizes
for 7 Fr double lumen arterial cannula drainage lumen
ECMO venous
cannula size [Fr]
Extracorporeal blood flow
1 L/min 2 L/min 3 L/min 4 L/min 5 L/min
Withdrawn blood volume during single cardiac cycle [ml]
18 0.922 1.168 1.404 1.641 1.866
19 0.903 1.126 1.336 1.545 1.740
20 0.887 1.092 1.282 1.468 1.640
21 0.876 1.067 1.241 1.411 1.565
22 0.866 1.047 1.208 1.365 1.505
23 0.859 1.030 1.181 1.327 1.456
24 0.853 1.017 1.161 1.298 1.418
25 0.848 1.007 1.144 1.274 1.387
26 0.844 0.998 1.129 1.254 1.361
27 0.841 0.991 1.118 1.238 1.339
28 0.838 0.985 1.108 1.224 1.322
29 0.836 0.980 1.100 1.213 1.307
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Table 9: The results of simulation with applying from 18 Fr to 29 Fr venous cannula sizes
for 8 Fr double lumen arterial cannula drainage lumen
ECMO venous
cannula size [Fr]
Extracorporeal blood flow
1 L/min 2 L/min 3 L/min 4 L/min 5 L/min
Withdrawn blood volume during single cardiac cycle [ml]
18 1.578 2 2.404 2.81 3.194
19 1.547 1.930 2.290 2.648 2.983
20 1.523 1.875 2.199 2.520 2.815
21 1.504 1.833 2.131 2.423 2.688
22 1.489 1.799 2.076 2.346 2.587
23 1.477 1.772 2.032 2.283 2.504
24 1.468 1.750 1.997 2.233 2.440
25 1.460 1.733 1.968 2.193 2.387
26 1.453 1.718 1.944 2.159 2.342
27 1.448 1.706 1.925 2.131 2.307
28 1.444 1.696 1.909 2.109 2.277
29 1.440 1.688 1.895 2.089 2.251
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Table 10: The results of simulation with applying from 18 Fr to 29 Fr venous cannula sizes
for 9 Fr double lumen arterial cannula drainage lumen
ECMO venous
cannula size [Fr]
Extracorporeal blood flow
1 L/min 2 L/min 3 L/min 4 L/min 5 L/min
Withdrawn blood volume during single cardiac cycle [ml]
18 2.490 3.155 3.791 4.432 5.038
19 2.446 3.051 3.619 4.186 4.714
20 2.410 2.968 3.482 3.989 4.456
21 2.384 2.905 3.377 3.840 4.260
22 2.363 2.854 3.294 3.722 4.104
23 2.345 2.813 3.226 3.624 3.976
24 2.332 2.781 3.172 3.547 3.876
25 2.330 2.754 3.128 3.485 3.794
26 2.311 2.732 3.092 3.432 3.724
27 2.303 2.714 3.062 3.390 3.669
28 2.297 2.699 3.037 3.355 3.623
29 2.292 2.686 3.016 3.325 3.583
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Appendix G: Percentage of LV unloading by DLAC with
applying from 18 Fr to 29 Fr venous cannula sizes, as-
sessed by mathematical modeling
Table 11: Percentage of left ventricular unloading by 5 Fr double lumen arterial cannula
drainage lumen, with applying from 18 Fr to 29 Fr venous cannula sizes
ECMO venous
cannula size [Fr]
Extracorporeal blood flow
2 L/min 3 L/min 4 L/min 5 L/min
LV unloading [%]
18 5 4 3 3
19 5 4 3 2
20 5 3 3 2
21 5 3 3 2
22 5 3 3 2
23 5 3 3 2
24 4 3 2 2
25 4 3 2 2
26 4 3 2 2
27 4 3 2 2
28 4 3 2 2
29 4 3 2 2
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Table 12: Percentage of left ventricular unloading by 6 Fr double lumen arterial cannula
drainage lumen, with applying from 18 Fr to 29 Fr venous cannula sizes
ECMO venous
cannula size [Fr]
Extracorporeal blood flow
2 L/min 3 L/min 4 L/min 5 L/min
LV unloading [%]
18 11 8 6 5
19 10 7 6 5
20 10 7 6 5
21 10 7 5 4
22 9 7 5 4
23 9 6 5 4
24 9 6 5 4
25 9 6 5 4
26 9 6 5 4
27 9 6 5 4
28 9 6 5 4
29 9 6 5 4
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Table 13: Percentage of left ventricular unloading by 7 Fr double lumen arterial cannula
drainage lumen, with applying from 18 Fr to 29 Fr venous cannula sizes
ECMO venous
cannula size [Fr]
Extracorporeal blood flow
2 L/min 3 L/min 4 L/min 5 L/min
LV unloading [%]
18 19 14 12 10
19 19 13 11 9
20 18 13 10 9
21 18 12 10 8
22 17 12 10 8
23 17 12 9 8
24 17 12 9 7
25 17 11 9 7
26 17 11 9 7
27 17 11 9 7
28 16 11 9 7
29 16 11 9 7
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Table 14: Percentage of left ventricular unloading by 8 Fr double lumen arterial cannula
drainage lumen, with applying from 18 Fr to 29 Fr venous cannula sizes
ECMO venous
cannula size [Fr]
Extracorporeal blood flow
2 L/min 3 L/min 4 L/min 5 L/min
LV unloading [%]
18 33 24 20 17
19 32 23 19 16
20 31 22 18 15
21 31 21 17 14
22 30 21 17 14
23 30 20 16 13
24 29 20 16 13
25 29 20 16 13
26 29 19 15 12
27 28 19 15 12
28 28 19 15 12
29 28 19 15 12
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Table 15: Percentage of left ventricular unloading by 9 Fr double lumen arterial cannula
drainage lumen, with applying from 18 Fr to 29 Fr venous cannula sizes
ECMO venous
cannula size [Fr]
Extracorporeal blood flow
2 L/min 3 L/min 4 L/min 5 L/min
LV unloading [%]
18 53 38 32 27
19 51 36 30 25
20 49 35 28 23
21 48 34 27 22
22 48 33 27 22
23 47 32 26 21
24 46 32 25 20
25 46 31 25 20
26 46 31 25 20
27 45 31 24 19
28 45 30 24 19
29 45 30 24 19
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Table 16: Percentage of left ventricular unloading by 10 Fr double lumen arterial cannula
drainage lumen, with applying from 18 Fr to 29 Fr venous cannula sizes
ECMO venous
cannula size [Fr]
Extracorporeal blood flow
2 L/min 3 L/min 4 L/min 5 L/min
LV unloading [%]
18 79 57 47 40
19 76 54 45 37
20 74 52 43 35
21 73 51 41 34
22 72 50 40 33
23 71 49 39 32
24 70 48 38 31
25 69 47 38 30
26 69 47 37 30
27 68 46 37 29
28 68 46 36 29
29 68 46 36 29
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